

Emphasizing HPV infection and the molecular processes in oral cancer development

Lucia Memè^{2*}
Pierluigi Marotti¹
Valeria Colonna¹
Micaela Del Vecchio¹
Nicola Sguera¹
Filippo Cardarelli¹
Fabrizio Bambini²
Ioana Roxana Bordea^{3*}
Erda Qorri⁴
Gustavo Vicentis Oliveira Fernandes⁵
Lwai Almasri⁷
Marwa Alkassab⁸
Maher Almasri⁸
Andrea Palermo⁶

- ¹ Department of Interdisciplinary Medicine, University of Bari "Aldo Moro" Bari, Italy.
² D.I.S.C.O. School of Dentistry, Polytechnic University of Marche, Ancona, Italy.
³ Department of Oral Rehabilitation, Faculty of Dentistry, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
⁴ Department of Dentistry, Faculty of Medical Sciences, Albanian University, Tirana, Albania.
⁵ Missouri School of Dentistry & Oral Health, A. T. Still University, MO, United States.
⁷ King's College London, U.K.
⁸ The University of Buckingham, U.K.
⁶ University of Salento, Lecce, Italy

Corresponding author: Ioana Roxana Bordea
e-mail: roxana.bordea@ymail.com

*These authors contributed equally as first authors.

Abstract

This research examines the epidemiological features and biomolecular mechanisms contributing to developing precancerous and cancerous conditions in oral lesions associated with Human Papillomavirus (HPV) infections. Existing literature highlights HPV's role in potentially malignant oral disorders. Consequently, the underlying biomolecular processes can initiate or contribute to benign lesions and oral carcinogenesis.

Keywords: HPV, Cancer, Infection

Introduction

Human Papillomavirus (HPV) infections represent a significant global health challenge, being associated with a wide range of diseases, including various types of cancer (1–9). HPV is a family of DNA viruses that show a particular tropism for epithelial cells of the skin and mucous membranes (10–20). There are over 200 HPV genotypes, some classified as low-risk (LR) and others as high-risk (HR) for cancer development (21–30).

Epidemiology

HPV infections are prevalent and often asymptomatic (31–41). It is estimated that about 80% of sexually active individuals will contract an HPV infection at some point in their lives (42–50). High-risk infections, such as those caused by HPV-16 and HPV-18 genotypes, are responsible for most cases of cervical cancer and are also associated with anogenital tumors, including those of the anus, vulva, vagina, and penis (51–60).

Authors

Pietro Lauria - Pierluigi Marotti - Valeria Colonna - Filippo Cardarelli - Nicola Sguera - Micaela Del Vecchio - Department of Interdisciplinary Medicine, University of Bari "Aldo Moro" Bari, Italy

Lucia Memè - Fabrizio Bambini - D.I.S.C.O. School of Dentistry, Polytechnic University of Marche, Ancona, Italy

Ioana Roxana Bordea - Department of Oral Rehabilitation, Faculty of Dentistry, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Erda Qorri - Department of Dentistry, Faculty of Medical Sciences, Albanian University, Tirana, Albania

Gustavo Vicentis Oliveira Fernandes - Missouri School of Dentistry & Oral Health, A. T. Still University, MO, United States

Lwai Almasri - King's College London, U.K.

Marwa Alkassab - Maher Almasri - The University of Buckingham, U.K.

Andrea Palermo - University of Salento, Lecce, Italy



License

This work is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](#).

Authors contributing to Oral and Implantology agree to publish their articles under the [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](#), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.

How to Cite

L. Memè, P. Marotti, V. Colonna, N. Sguera, F. Cardarelli, F. Bambini, I.R. Bordea, E. Qorri, G.V.O. Fernandes, M. Del Vecchio, L. Almasri, M. Alkassab, M. Almasri, A. Palermo.

Emphasizing HPV infection and the molecular processes in oral cancer development.

Oral and Implantology
Vol. 16 No. 3 (S1) (2024), 218-231.
[https://doi.org/10.11138/oi.v16i3 \(S1\).74](https://doi.org/10.11138/oi.v16i3 (S1).74)

Additionally, HPV has been identified as a significant etiological factor in head and neck cancers, particularly oropharyngeal cancer (61–70).

Epidemiology of Oral Cancer

Oral squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with an exceptionally high prevalence in Central-Southern and Eastern Asia (71–80). Mortality from oral cancer is significantly high, especially in Asian countries, where diagnosis often occurs in the advanced stages of the disease (81–90). Major risk factors include tobacco use, alcohol, betel quid, poor oral hygiene, malnutrition, and viral and bacterial infections (91–100, 294). These factors contribute to the malignant transformation of oral cells, leading to the development of SCC (101–110).

Role of HPV in Oral Carcinogenesis

HPVs are oncogenic viruses that can cause benign hyperplastic lesions, precancerous lesions, and cancerous lesions (111–120). The HPV genome comprises double-stranded DNA and encodes structural and regulatory proteins (121–130). The HPV E6 and E7 proteins are crucial in carcinogenesis. They inactivate the tumor suppressor proteins pRb and p53, promoting tumor growth (131–140). This inactivation allows cells to proliferate uncontrollably, leading to tumor formation (141–150).

Molecular Mechanisms

HPV E1 and E2 proteins are necessary for viral replication (151–166). The E5 protein activates the epidermal growth factor receptor (EGFR), promoting cell proliferation (167–173). The integration of HPV DNA into the host genome and the expression of E6 and E7 proteins are key events in cellular transformation (174–184). These proteins interact with cellular pathways, altering cell cycle regulation and promoting the survival of tumor cells (185–193).

Diagnosis and Detection

Molecular tests for HPV search for viral DNA sequences in tissues (194–198). PCR is a widely used technique for amplifying and detecting specific DNA sequences

(199,200). In the context of HPV, PCR can be used to identify the presence of viral DNA in tissue samples (201,202). This technique is relatively simple and rapid, but its sensitivity can vary depending on experimental conditions and sample quality. PCR is often used as an initial screening method for the presence of HPV in clinical samples (203,204). Digital droplet PCR (ddPCR) represents an evolution of traditional PCR and is considered one of the most sensitive techniques for detecting and quantifying viral DNA (205,206). ddPCR divides the sample into thousands of droplets, each containing a single DNA molecule (207). This approach allows for more precise quantification of viral DNA, even at low concentrations. ddPCR can detect a few copies of viral DNA, making it particularly useful for the early diagnosis and prognostic evaluation of patients with head and neck SCC (208). The precision and sensitivity of ddPCR are crucial for an accurate diagnosis, which can significantly improve patient treatment and prognosis (209–212).

Controversies and Challenges

The link between HPV and oral squamous cell carcinoma (SCC) is debated due to variations in sampling and detection methods (213,214). Key factors include the transmission of HPV through saliva and its presence in asymptomatic individuals (215). The prevalence of HPV in healthy oral mucosa varies, and there is no vertical transmission from mother to fetus, posing additional challenges in managing HPV infection. Further research is needed to resolve these issues and develop more effective management strategies.

Implications for Prevention

Developing preventative and therapeutic methods requires an understanding of the molecular underpinnings of HPV infection and its role in mouth carcinogenesis (217,218). HPV vaccination might considerably decrease the incidence of mouth cancer linked to HPV. Advanced molecular diagnostic tools can yield more precise prognostic information (222) and improve the clinical care of patients with head and neck SCC. Prevention through immunization and early diagnosis is essential to lower the illness burden and increase survival rates.




Figure 1

Preventive Strategies

One of the best ways to lower the incidence of HPV-associated mouth cancer is by HPV vaccination (223). High-risk oncogenic HPV infections, which account for a sizable portion of occurrences of mouth cancer, can be prevented with the use of current vaccinations (224). About 70% of cases of HPV-associated oral cancer are caused by HPV types 16 and 18, which are the targets of these vaccinations, which are intended to elicit an immune response against these viruses (225, 291).

Efficacy of HPV Vaccines

HPV vaccines, such as Gardasil and Cervarix, have shown high efficacy in preventing high-risk oncogenic HPV infections. Clinical studies indicate that these vaccines can reduce the incidence of precancerous lesions and associated tumors (226–228). Vaccination is also effective in preventing HPV infections in high-risk populations, such as young women and adolescents. Early vaccination, before exposure to the virus, is critical to maximize vaccine efficacy (229). The future of HPV vaccination includes the development of new vaccines that offer broader protection against a more significant number of HPV types (205, 230–232). For example, Gardasil 9 protects against nine high-risk HPV types, compared to the four types covered by the original version of Gardasil. This increased coverage can potentially prevent an even more significant percentage of HPV-associated cancer cases. Additionally, research continues to explore the use of HPV vaccines to prevent other types of cancer beyond cervical and oral cancers, such as anal, vulvar, and vaginal cancers (233–235, 292).

Global Vaccine Coverage

Even though HPV vaccinations are effective, vaccination rates vary widely worldwide. High vaccination coverage rates have been attained in several high-income nations, including Australia and the United Kingdom, with encouraging outcomes in lowering HPV infections and precancerous lesions (236). Nonetheless, vaccination rates are still low in many other areas. Due to obstacles such as the vaccine's high cost, inadequate healthcare infrastructure, and low vaccination knowledge, immunization is still not readily accessible or acceptable in many places (237).

Educational Efforts and Health Policies

Health policies and focused educational initiatives are required to increase vaccination coverage and lower the prevalence of mouth cancer (238). Campaigns to raise public knowledge of the advantages of HPV vaccination and the dangers of HPV infections should be a part of educational initiatives. Parents, teenagers, and medical professionals should all be the focus of these programs to ensure they have the knowledge they need to encourage vaccination (239). By offering free or inexpensive vaccinations, including vaccination into public health initiatives, and establishing infrastructure for vaccine delivery and distribution, health policy should work to increase the accessibility and affordability of HPV vaccines (240). Policies should also address cultural obstacles and vaccination-related worries to boost public trust in the efficacy and safety of vaccinations (240–242).

Treatment of Oral Cancer

The location of the tumor, the patient's overall health, and the stage of the disease all contribute to the complicated treatment of oral cancer. Surgery, radiation, chemotherapy, and targeted treatments are available. Every strategy has benefits and drawbacks, and therapies are frequently combined to optimize effectiveness and enhance patient outcomes (243–246).

- Surgery is usually the initial treatment for oral cancer, mainly if the tumor is accessible and confined. The primary tumor and, if required, any adjacent lymph nodes that could be impacted must be removed. If the tumor is large, more involved operations, such as removing a portion of the tongue, jaw, or other anatomical components, can be necessary. Surgery may be followed by further treatments to get rid of any leftover tumor cells (247–249).
- Radiotherapy: This method kills tumor cells using high-energy radiation. It can be administered alone or in conjunction with chemotherapy and surgery. Radiotherapy is especially helpful for treating regions that are hard to access through surgery or shrinking the tumor before surgery (250–253). However, it has serious adverse effects, such as taste changes, xerostomia (dry mouth), and mucositis (inflammation of the mucous membranes) (254–263).
- Chemotherapy: This treatment uses medications to eradicate or inhibit malignant cell development (264–270). It can be given intravenously, orally, or by other means. To boost the effectiveness of the treatment, chemotherapy and radiation are sometimes combined (chemoradiotherapy) (271–275). Chemotherapy, however, can cause serious adverse effects, such as immunosuppression, nausea, vomiting, and hair loss (276–283).
- Targeted Therapies: A class of medical interventions known as targeted therapies target specific molecular targets implicated in the development and metastasis of cancer (284–290). Targeted treatments for oral cancer include cetuximab and other inhibitors of the epidermal growth factor receptor (EGFR). By blocking signals that encourage tumor cell development, these medications increase the effectiveness of therapy. To improve patient results, targeted therapies can be used with other treatments.

Future Research

To create more efficient management plans for HPV infection, additional study is required to resolve the issues and shed light on the disputes surrounding the virus. Addressing this global health issue requires ongoing research and innovation in diagnosis and treatment. Future research should concentrate on locating particular HPV biomarkers, creating fresh, focused treatments, and refining immunization plans.

9. Conclusions

The article provides a thorough summary of HPV infections and the molecular processes that contribute to mouth cancer. Understanding these pathways is essential for improving HPV-associated oral cancer prevention, diagnosis, and therapy. Further research is needed to address issues related to the virus and

resolve disagreements. Diagnostic and therapeutic research and innovation must continue to address this global health concern.

Abbreviations

HPV	Human Papillomavirus
SCC	Squamous Cell Carcinoma
LR	Low-Risk
HR	High-Risk
EGFR	Epidermal Growth Factor Receptor
PCR	Polymerase Chain Reaction
ddPCR	Digital Droplet Polymerase Chain Reaction
EGFR	Epidermal Growth Factor Receptor

Funding

No funds are available for this study

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

- Rosa, M.; Mohammadi, A. Cervical Cytology and Human Papillomavirus Testing in Adolescent Women: Implications in Management of a Positive HPV Test. *Patholog Res Int* 2014, 2014, 165690, doi:10.1155/2014/165690.
- Joura, E.A.; Giuliano, A.R.; Iversen, O.-E.; Bouchard, C.; Mao, C.; Mehlsen, J.; Moreira, E.D.; Ngan, Y.; Petersen, L.K.; Lazcano-Ponce, E.; et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. *N Engl J Med* 2015, 372, 711–723, doi:10.1056/NEJMoa1405044.
- Laforgia, A.; Dipalma, G.; Inchegolo, A.D.; Ciccarese, D.; Marotti, P.; Corsalini, M.; Paduanelli, G.; Tari, S.R.; Scarano, R.; Postiglione, F.; et al. A CASE REPORT ABOUT MULTIPLE SUPERNUMERARY TEETH NOT ASSOCIATED WITH SYNDROMES IN A FAMILY WITH A NORMAL KARYOTYPE. 2023.
- Koutsky, L.A.; Ault, K.A.; Wheeler, C.M.; Brown, D.R.; Barr, E.; Alvarez, F.B.; Chiocchierini, L.M.; Jansen, K.U.; Proof of Principle Study Investigators A Controlled Trial of a Human Papillomavirus Type 16 Vaccine. *N Engl J Med* 2002, 347, 1645–1651, doi:10.1056/NEJMoa020586.
- Ault, K.A.; Giuliano, A.R.; Edwards, R.P.; Tamms, G.; Kim, L.-L.; Smith, J.F.; Jansen, K.U.; Allende, M.; Taddeo, F.J.; Skulsky, D.; et al. A Phase I Study to Evaluate a Human Papillomavirus (HPV) Type 18 L1 VLP Vaccine. *Vaccine* 2004, 22, 3004–3007, doi:10.1016/j.vaccine.2004.02.020.
- Stevanović, S.; Helman, S.R.; Wunderlich, J.R.; Langhan, M.M.; Doran, S.L.; Kwong, M.L.M.; Somerville, R.P.T.; Klebanoff, C.A.; Kammula, U.S.; Sherry, R.M.; et al. A Phase II Study of Tumor-Infiltrating Lymphocyte Therapy for Human Papillomavirus-Associated Epithelial Cancers. *Clin Cancer Res* 2019, 25, 1486–1493, doi:10.1158/1078-0432.CCR-18-2722.
- Guo, X.; Qiu, L.; Wang, Y.; Wang, Y.; Wang, Q.; Song, L.; Li, Y.; Huang, K.; Du, X.; Fan, W.; et al. A Randomized Open-Label Clinical Trial of an Anti-HPV Biological Dressing (JB01-BD) Administered Intravaginally to Treat High-Risk HPV Infection. *Microbes Infect* 2016, 18, 148–152, doi:10.1016/j.micinf.2015.10.004.
- Anderson, J.S.; Hoy, J.; Hillman, R.; Barnden, M.; Eu, B.; McKenzie, A.; Gittleson, C. A Randomized, Placebo-controlled, Dose-Escalation Study to Determine the Safety, Tolerability, and Immunogenicity of an HPV-16 Therapeutic Vaccine in HIV-Positive Participants with Oncogenic HPV Infection of the Anus. *J Acquir Immune Defic Syndr* 2009, 52, 371–381, doi:10.1097/QAI.0b013e3181b7354c.
- Adjei Boakye, E.; Tobo, B.B.; Rojek, R.P.; Mohammed, K.A.; Geneus, C.J.; Osazuwa-Peters, N. Approaching a Decade since HPV Vaccine Licensure: Racial and Gender Disparities in Knowledge and Awareness of HPV and HPV Vaccine. *Hum Vaccin Immunother* 2017, 13, 2713–2722, doi:10.1080/21645515.2017.1363133.
- Abedin, S.; Paul, S.K.; Haque, N.; Ahmed, S.; Nasreen, S.A.; Akhter, N.; Haque, N.; Sarkar, S.R.; Roy, S.; Nahar, F.; et al. Distribution of HPV-16 and HPV-18 from the Patients Attending At Mymensingh Medical College Hospital by Newly Developed Oncoprotein Detection Assay. *Mymensingh Med J* 2019, 28, 31–36.
- Naghshfar, Z.S.; Rosenshein, N.B.; Lorincz, A.T.; Buscema, J.; Shah, K.V. Characterization of Human Papillomavirus Type 45, a New Type 18-Related Virus of the Genital Tract. *J Gen Virol* 1987, 68 (Pt 12), 3073–3079, doi:10.1099/0022-1317-68-12-3073.
- Herrington, C.S.; de Angelis, M.; Evans, M.F.; Troncone, G.; McGee, J.O. Detection of High Risk Human Papillomavirus in Routine Cervical Smears: Strategy for Screening. *J Clin Pathol* 1992, 45, 385–390, doi:10.1136/jcp.45.5.385.
- Teixeira, C.S.C.; Teixeira, J.C.; Oliveira, E.R.Z.M.; Machado, H.C.; Zeferino, L.C. Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-Year Follow-Up after Vaccination against HPV 16/18. *Rev Bras Ginecol Obstet* 2017, 39, 408–414, doi:10.1055/s-0037-1604133.
- Iwasawa, A.; Kumamoto, Y.; Hirose, T.; Tsukamoto, T.; Gohro, T.; Ikegaki, S.; Saka, T.; Minami, K.; Fujinaga, K. (Detection of human papillomavirus DNA in cases of sexually transmitted diseases (STD)). *Kansenshogaku Zasshi* 1992, 66, 165–171, doi:10.11150/kansenshogakuzasshi1970.66.165.
- Leiserowitz, G.S.; Hall, K.S.; Foster, C.A.; Hitchcock, M.E.; Christensen, N.D.; Heim, K.; Smith, L.H. Detection of Serologic Neutralizing Antibodies against HPV-11 in Patients with Condyloma Acuminata and Cervical Dysplasia Using an in Vitro Assay. *Gynecol Oncol* 1997, 66, 295–299, doi:10.1006/gyno.1997.4743.
- Kjaer, S.K.; van den Brule, A.J.; Bock, J.E.; Poll, P.A.; Engholm, G.; Sherman, M.E.; Walboomers, J.M.; Meijer, C.J. Determinants for Genital Human Papillomavirus (HPV) Infection in 1000 Randomly Chosen Young Danish Women with Normal Pap Smear: Are There Different Risk Profiles for Oncogenic and Nononcogenic HPV Types? *Cancer Epidemiol Biomarkers Prev* 1997, 6, 799–805.
- El-Zein, M.; Ramanakumar, A.V.; Naud, P.; Roteli-Martins, C.M.; de Carvalho, N.S.; Colares de Borba, P.; Teixeira, J.C.; Moscicki, A.-B.; Harper, D.M.; Tyring, S.K.; et al. Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. *Sex Transm Dis* 2019, 46, 663–669, doi:10.1097/OLQ.0000000000001053.
- Aynaud, O.; Piron, D.; Bijaoui, G.; Casanova, J.M. Developmental Factors of Urethral Human Papillomavirus Lesions: Correlation with Circumcision. *BJU Int* 1999, 84, 57–60, doi:10.1046/j.1464-410x.1999.00104.x.
- Godoy-Vitorino, F.; Ortiz-Morales, G.; Romaguera, J.; Sanchez, M.M.; Martinez-Ferrer, M.; Chorna, N. Discriminating High-Risk Cervical Human Papilloma Virus Infections with Urinary Biomarkers via Non-Targeted GC-MS-Based Metabolomics. *PLoS One* 2018, 13, e0209936, doi:10.1371/journal.pone.0209936.
- Sugase, M.; Matsukura, T. Distinct Manifestations of Human Papillomaviruses in the Vagina. *Int J Cancer* 1997, 72, 412–415, doi:10.1002/(sici)1097-0215(19970729)72:3<412::aid-ijc7>3.0.co;2-s.
- Paavonen, J.; Naud, P.; Salmerón, J.; Wheeler, C.M.; Chow, S.-N.; Apter, D.; Kitchener, H.; Castellsague, X.; Teixeira, J.C.; Skinner, S.R.; et al. Efficacy of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine against Cervical Infection and Precancer Caused by

- 301–314, doi:10.1016/S0140-6736(09)61248-4.
22. Navarro-Illana, P.; Navarro-Illana, E.; Vila-Candel, R.; Díez-Domingo, J. Drivers for Human Papillomavirus Vaccination in Valencia (Spain). *Gac Sanit* 2018, 32, 454–458, doi:10.1016/j.gaceta.2017.05.008.
 23. Krings, A.; Boateng, G.; Dunyo, P.; Amuah, J.E.; Adams, R.A.; Adunyame, L.; Nkansah, D.O.; Wormenor, C.M.; Hansen, B.T.; Gedzah, I.; et al. Dynamics of Genotype-Specific HPV Clearance and Reinfection in Rural Ghana May Compromise HPV Screening Approaches. *Papillomavirus Res* 2019, 7, 45–51, doi:10.1016/j.pvr.2018.12.004.
 24. Acosta-Rios, M.P.; Sauer-Ramírez, E.; Castro-Muñoz, L.J.; García-Solís, M.; Gómez-García, C.; Ocadiz-Delgado, R.; Martínez-Martínez, A.; Sánchez-Monroy, V.; Pérez-De la Mora, C.; Correa-Meza, B.; et al. Effect of Dialyzable Leukocyte Extract on Chronic Cervicitis in Patients with HPV Infection. *J Med Life* 2017, 10, 237–243.
 25. Nejmark, B.A.; Kondrat'eva, J.S.; Zologina, V.S.; Torbik, D.V. (EFFECTIVENESS OF COMBINED TREATMENT OF HPV INFECTION). *Urologija* 2015, 39–40, 42.
 26. Carozzi, F.M.; Ocello, C.; Burroni, E.; Faust, H.; Zappa, M.; Paci, E.; Iossa, A.; Bonanni, P.; Confortini, M.; Sani, C. Effectiveness of HPV Vaccination in Women Reaching Screening Age in Italy. *J Clin Virol* 2016, 84, 74–81, doi:10.1016/j.jcv.2016.09.011.
 27. Lehtinen, M.; Apter, D.; Eriksson, T.; Harjula, K.; Hokkanen, M.; Lehtinen, T.; Natunen, K.; Damaso, S.; Soila, M.; Bi, D.; et al. Effectiveness of the AS04-Adjuvanted HPV-16/18 Vaccine in Reducing Oropharyngeal HPV Infections in Young Females—Results from a Community-Randomized Trial. *Int J Cancer* 2020, 147, 170–174, doi:10.1002/ijc.32791.
 28. Kreimer, A.R.; González, P.; Katki, H.A.; Porras, C.; Schiffman, M.; Rodriguez, A.C.; Solomon, D.; Jiménez, S.; Schiller, J.T.; Lowy, D.R.; et al. Efficacy of a Bivalent HPV 16/18 Vaccine against Anal HPV 16/18 Infection among Young Women: A Nested Analysis within the Costa Rica Vaccine Trial. *Lancet Oncol* 2011, 12, 862–870, doi:10.1016/S1470-2045(11)70213-3.
 29. Harper, D.M.; Franco, E.L.; Wheeler, C.; Ferris, D.G.; Jenkins, D.; Schuind, A.; Zahaf, T.; Innis, B.; Naud, P.; De Carvalho, N.S.; et al. Efficacy of a Bivalent L1 Virus-like Particle Vaccine in Prevention of Infection with Human Papillomavirus Types 16 and 18 in Young Women: A Randomised Controlled Trial. *Lancet* 2004, 364, 1757–1765, doi:10.1016/S0140-6736(04)17398-4.
 30. Magnan, S.; Tota, J.E.; El-Zein, M.; Burchell, A.N.; Schiller, J.T.; Ferenczy, A.; Tellier, P.-P.; Coutlée, F.; Franco, E.L.; CATCH Study Group. Efficacy of a Carrageenan Gel Against Transmission of Cervical HPV (CATCH): Interim Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase 2B Trial. *Clin Microbiol Infect* 2019, 25, 210–216, doi:10.1016/j.cmi.2018.04.012.
 31. Castle, P.E.; Burk, R.D.; Massad, L.S.; Eltoum, I.-E.; Hall, C.B.; Hessel, N.A.; Anastos, K.; Xie, X.; Minkoff, H.; Xue, X.; et al. Epidemiological Evidence That Common HPV Types May Be Common Because of Their Ability to Evade Immune Surveillance: Results from the Women's Interagency HIV Study. *Int J Cancer* 2020, 146, 3320–3328, doi:10.1002/ijc.32693.
 32. Apter, D.; Wheeler, C.M.; Paavonen, J.; Castellsagué, X.; Garland, S.M.; Skinner, S.R.; Naud, P.; Salmerón, J.; Chow, S.-N.; Kitchener, H.C.; et al. Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. *Clin Vaccine Immunol* 2015, 22, 361–373, doi:10.1128/CVI.00591-14.
 33. Giuliano, A.R.; Palefsky, J.M.; Goldstone, S.; Moreira, E.D.; Penny, M.E.; Aranda, C.; Vardas, E.; Moi, H.; Jessen, H.; Hillman, R.; et al. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. *N Engl J Med* 2011, 364, 401–411, doi:10.1056/NEJMoa0909537.
 34. Hildesheim, A.; Wacholder, S.; Catteau, G.; Struyf, F.; Dubin, G.; Herrero, R.; CVT Group. Efficacy of the HPV-16/18 Vaccine: Final According to Protocol Results from the Blinded Phase of the Randomized Costa Rica HPV-16/18 Vaccine Trial. *Vaccine* 2014, 32, 5087–5097, doi:10.1016/j.vaccine.2014.06.038.
 35. Konno, R.; Yoshikawa, H.; Okutani, M.; Quint, W.; V Suryakiran, P.; Lin, L.; Struyf, F. Efficacy of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine against Cervical Intraepithelial Neoplasia and Cervical Infection in Young Japanese Women. *Hum Vaccin Immunother* 2014, 10, 1781–1794, doi:10.4161/hv.28712.
 36. Szarewski, A.; Poppe, W. a. J.; Skinner, S.R.; Wheeler, C.M.; Paavonen, J.; Naud, P.; Salmerón, J.; Chow, S.-N.; Apter, D.; Kitchener, H.; et al. Efficacy of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Women Aged 15–25 Years with and without Serological Evidence of Previous Exposure to HPV-16/18. *Int J Cancer* 2012, 131, 106–116, doi:10.1002/ijc.26362.
 37. Zhu, F.-C.; Hu, S.-Y.; Hong, Y.; Hu, Y.-M.; Zhang, X.; Zhang, Y.-J.; Pan, Q.-J.; Zhang, W.-H.; Zhao, F.-H.; Zhang, C.-F.; et al. Efficacy, Immunogenicity and Safety of the AS04-HPV-16/18 Vaccine in Chinese Women Aged 18–25 Years: End-of-Study Results from a Phase II/III, Randomised, Controlled Trial. *Cancer Med* 2019, 8, 6195–6211, doi:10.1002/cam4.2399.
 38. Zhu, F.-C.; Chen, W.; Hu, Y.-M.; Hong, Y.; Li, J.; Zhang, X.; Zhang, Y.-J.; Pan, Q.-J.; Zhao, F.-H.; Yu, J.-X.; et al. Efficacy, Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine in Healthy Chinese Women Aged 18–25 Years: Results from a Randomized Controlled Trial. *Int J Cancer* 2014, 135, 2612–2622, doi:10.1002/ijc.28897.
 39. Mikamo, H.; Yamagishi, Y.; Murata, S.; Yokokawa, R.; Han, S.R.; Wakana, A.; Sawata, M.; Tanaka, Y. Efficacy, Safety, and Immunogenicity of a Quadrivalent HPV Vaccine in Japanese Men: A Randomized, Phase 3, Placebo-Controlled Study. *Vaccine* 2019, 37, 1651–1658, doi:10.1016/j.vaccine.2019.01.069.
 40. Wheeler, C.M.; Skinner, S.R.; Del Rosario-Raymundo, M.R.; Garland, S.M.; Chatterjee, A.; Lazcano-Ponce, E.; Salmerón, J.; McNeil, S.; Stapleton, J.T.; Bouchard, C.; et al. Efficacy, Safety, and Immunogenicity of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Women Older than 25 Years: 7-Year Follow-up of the Phase 3, Double-Blind, Randomised Controlled VIVIANE Study. *Lancet Infect Dis* 2016, 16, 1154–1168, doi:10.1016/S1473-3099(16)30120-7.
 41. Shukla, S.; Bharti, A.C.; Hussain, S.; Mahata, S.; Hedau, S.; Kailash, U.; Kashyap, V.; Bhamhani, S.; Roy, M.; Batra, S.; et al. Elimination of High-Risk Human Papillomavirus Type HPV16 Infection by "Praneem" Polyherbal Tablet in Women with Early Cervical Intraepithelial Lesions. *J Cancer Res Clin Oncol* 2009, 135, 1701–1709, doi:10.1007/s00432-009-0617-1.
 42. Coseo, S.E.; Porras, C.; Dodd, L.E.; Hildesheim, A.; Rodriguez, A.C.; Schiffman, M.; Herrero, R.; Wacholder, S.; González, P.; Sherman, M.E.; et al. Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure. *Sex Transm Dis* 2011, 38, 976–982, doi:10.1097/OLQ.0b013e31822545c0.
 43. Cab-Sánchez, B.G.; Hernández-Solis, S.E.; Rueda-Gordillo, F.; Conde-Ferráez, L.; Gómez-Carballo, J.G.; González-Losa, M.D.R. (Epidemiology of oral HPV infection in young healthy individuals). *Rev Chilena Infectol* 2017, 34, 557–562, doi:10.4067/S0716-10182017000600557.
 44. Lefevre, M.; Rousseau, A.; Rayon, T.; Dalstein, V.; Clavel, C.; Beby-Defaux, A.; Pretet, J.-L.; Soussan, P.; Polette, M.; Lacau Saint Guily, J.; et al. Epithelial to Mesenchymal Transition and HPV Infection in Squamous Cell Oropharyngeal Carcinomas: The Papillophar Study. *Br J Cancer* 2017, 116, 362–369, doi:10.1038/bjc.2016.434.
 45. Kiani, A.K.; Pheby, D.; Henehan, G.; Brown, R.; Sieving, P.; Sykora, P.; Marks, R.; Falsini, B.; Capodicasa, N.; Miertus, S.; et al. Ethical Considerations Regarding Animal Experimentation. *J Prev Med Hyg* 2022, 63, E255–E266, doi:10.15167/2421-4248/jpmh2022.63.2S3.2768.
 46. Kepka, D.; Coronado, G.D.; Rodriguez, H.P.; Thompson, B. Evaluation of a Radionovela to Promote HPV Vaccine Awareness and Knowledge among Hispanic Parents.

- J Community Health 2011, 36, 957–965, doi:10.1007/s10900-011-9395-1.
47. Gray, P.; Palmroth, J.; Luostarinen, T.; Apter, D.; Dubin, G.; Garnett, G.; Eriksson, T.; Natunen, K.; Merikukka, M.; Pimenoff, V.; et al. Evaluation of HPV Type-Replacement in Unvaccinated and Vaccinated Adolescent Females-Post-Hoc Analysis of a Community-Randomized Clinical Trial (II). *Int J Cancer* 2018, 142, 2491–2500, doi:10.1002/ijc.31281.
 48. Wright, T.C.; Stoler, M.H.; Sharma, A.; Zhang, G.; Behrens, C.; Wright, T.L.; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women with High-Risk HPV+ Cytology-Negative Results. *Am J Clin Pathol* 2011, 136, 578–586, doi:10.1309/AJCP7US5EXAS6DKZ.
 49. Olsson, S.-E.; Kjaer, S.K.; Sigurdsson, K.; Iversen, O.-E.; Hernandez-Avila, M.; Wheeler, C.M.; Perez, G.; Brown, D.R.; Koutsky, L.A.; Tay, E.H.; et al. Evaluation of Quadrivalent HPV 6/11/16/18 Vaccine Efficacy against Cervical and Anogenital Disease in Subjects with Serological Evidence of Prior Vaccine Type HPV Infection. *Hum Vaccin* 2009, 5, 696–704, doi:10.4161/hv.10.9515.
 50. Padalko, E.; Ali-Risasi, C.; Van Renterghem, L.; Bamelis, M.; De Mey, A.; Sturtewagen, Y.; Vastenavond, H.; Vanden Broeck, D.; Weyers, S.; Praet, M. Evaluation of the Clinical Significance of Human Papillomavirus (HPV) 53. *Eur J Obstet Gynecol Reprod Biol* 2015, 191, 7–9, doi:10.1016/j.ejogrb.2015.04.004.
 51. Lie, A.K.; Tropé, A.; Skare, G.B.; Bjørge, T.; Jonassen, C.M.; Brusegard, K.; Lönnberg, S. HPV Genotype Profile in a Norwegian Cohort with ASC-US and LSIL Cytology with Three Year Cumulative Risk of High Grade Cervical Neoplasia. *Gynecol Oncol* 2018, 148, 111–117, doi:10.1016/j.ygyno.2017.10.031.
 52. Kreimer, A.R.; Herrero, R.; Sampson, J.N.; Porras, C.; Lowy, D.R.; Schiller, J.T.; Schiffman, M.; Rodriguez, A.C.; Chanock, S.; Jimenez, S.; et al. Evidence for Single-Dose Protection by the Bivalent HPV Vaccine—Review of the Costa Rica HPV Vaccine Trial and Future Research Studies. *Vaccine* 2018, 36, 4774–4782, doi:10.1016/j.vaccine.2017.12.078.
 53. Zammit, A.P.; Sinha, R.; Cooper, C.L.; Perry, C.F.L.; Frazer, I.H.; Tuong, Z.K. Examining the Contribution of Smoking and HPV towards the Etiology of Oral Cavity Squamous Cell Carcinoma Using High-Throughput Sequencing: A Prospective Observational Study. *PLoS One* 2018, 13, e0205406, doi:10.1371/journal.pone.0205406.
 54. Minervini, G. Feature Paper in Oral Physiology and Pathology. *Life (Basel)* 2024, 14, 895, doi:10.3390/life14070895.
 55. Huh, W.K.; Joura, E.A.; Giuliano, A.R.; Iversen, O.-E.; de Andrade, R.P.; Ault, K.A.; Bartholomew, D.; Cestero, R.M.; Fedrizzi, E.N.; Hirschberg, A.L.; et al. Final Efficacy, Immunogenicity, and Safety Analyses of a Nine-Valent Human Papillomavirus Vaccine in Women Aged 16–26 Years: A Randomised, Double-Blind Trial. *Lancet* 2017, 390, 2143–2159, doi:10.1016/S0140-6736(17)31821-4.
 56. Vrtačnik Bokal, E.; Kocjan, B.J.; Poljak, M.; Bogovac, Z.; Jančar, N. Genomic Variants of Human Papillomavirus Genotypes 16, 18, and 33 in Women with Cervical Cancer in Slovenia. *J Obstet Gynaecol Res* 2010, 36, 1204–1213, doi:10.1111/j.1447-0756.2010.01316.x.
 57. Watson-Jones, D.; Baisley, K.; Brown, J.; Kavishe, B.; Andreasen, A.; Changalucha, J.; Mayaud, P.; Kapiga, S.; Gumodoka, B.; Hayes, R.J.; et al. High Prevalence and Incidence of Human Papillomavirus in a Cohort of Healthy Young African Female Subjects. *Sex Transm Infect* 2013, 89, 358–365, doi:10.1136/sexttrans-2012-050685.
 58. Mboumba Bouassa, R.-S.; Nodjikouambaye, Z.A.; Sadjoli, D.; Adawaye, C.; Péré, H.; Veyer, D.; Matta, M.; Robin, L.; Toné-Wolyec, S.; Moussa, A.M.; et al. High Prevalence of Cervical High-Risk Human Papillomavirus Infection Mostly Covered by Gardasil-9 Prophylactic Vaccine in Adult Women Living in N'Djamena, Chad. *PLoS One* 2019, 14, e0217486, doi:10.1371/journal.pone.0217486.
 59. Longatto-Filho, A.; Hammes, L.S.; Sarian, L.O.; Roteli-Martins, C.; Derchain, S.F.M.; Eržen, M.; Branca, M.; Tatti, S.; Naud, P.; de Matos, J.C.; et al. Hormonal Contraceptives and the Length of Their Use Are Not Independent Risk Factors for High-Risk HPV Infections or High-Grade CIN. *Gynecol Obstet Invest* 2011, 71, 93–103, doi:10.1159/000320742.
 60. Joura, E.A.; Kjaer, S.K.; Wheeler, C.M.; Sigurdsson, K.; Iversen, O.-E.; Hernandez-Avila, M.; Perez, G.; Brown, D.R.; Koutsky, L.A.; Tay, E.H.; et al. HPV Antibody Levels and Clinical Efficacy Following Administration of a Prophylactic Quadrivalent HPV Vaccine. *Vaccine* 2008, 26, 6844–6851, doi:10.1016/j.vaccine.2008.09.073.
 61. Polman, N.J.; Veldhuijzen, N.J.; Heideman, D.A.M.; Snijders, P.J.F.; Meijer, C.J.L.M.; Berkhof, J. HPV-Positive Women with Normal Cytology Remain at Increased Risk of CIN3 after a Negative Repeat HPV Test. *Br J Cancer* 2017, 117, 1557–1561, doi:10.1038/bjc.2017.309.
 62. Chan, J.K.; Monk, B.J.; Brewer, C.; Keefe, K.A.; Osann, K.; McMeekin, S.; Rose, G.S.; Youssef, M.; Wilczynski, S.P.; Meyskens, F.L.; et al. HPV Infection and Number of Lifetime Sexual Partners Are Strong Predictors for “natural” Regression of CIN 2 and 3. *Br J Cancer* 2003, 89, 1062–1066, doi:10.1038/sj.bjc.6601196.
 63. Serour, Y.; Bendahmane, M.; Abbou Baker, F.; Medles, M.; Moueddene, B.; Kraiba, R. HPV Test by Hybrid Capture II for the Diagnosis of HR-HPV Persistent Infection. *Med Mal Infect* 2017, 47, 484–489, doi:10.1016/j.medmal.2017.05.013.
 64. Gilham, C.; Sargent, A.; Kitchener, H.C.; Peto, J. HPV Testing Compared with Routine Cytology in Cervical Screening: Long-Term Follow-up of ARTISTIC RCT. *Health Technol Assess* 2019, 23, 1–44, doi:10.3310/hta23280.
 65. Bruggink, S.C.; Gussekloo, J.; de Koning, M.N.C.; Feitkamp, M.C.W.; Bavinck, J.N.B.; Quint, W.G.V.; Assendelft, W.J.J.; Eekhof, J.A.H. HPV Type in Plantar Warts Influences Natural Course and Treatment Response: Secondary Analysis of a Randomised Controlled Trial. *J Clin Virol* 2013, 57, 227–232, doi:10.1016/j.jcv.2013.02.021.
 66. Juraskova, I.; O'Brien, M.; Mullan, B.; Bari, R.; Laidsaar-Powell, R.; McCaffery, K. HPV Vaccination and the Effect of Information Framing on Intentions and Behaviour: An Application of the Theory of Planned Behaviour and Moral Norm. *Int J Behav Med* 2012, 19, 518–525, doi:10.1007/s12529-011-9182-5.
 67. Palefsky, J.M.; Giuliano, A.R.; Goldstone, S.; Moreira, E.D.; Aranda, C.; Jessen, H.; Hillman, R.; Ferris, D.; Coutlee, F.; Stoler, M.H.; et al. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. *N Engl J Med* 2011, 365, 1576–1585, doi:10.1056/NEJMoa1010971.
 68. Griesser, H.; Sander, H.; Walczak, C.; Hilfrich, R.A. HPV Vaccine Protein L1 Predicts Disease Outcome of High-Risk HPV+ Early Squamous Dysplastic Lesions. *Am J Clin Pathol* 2009, 132, 840–845, doi:10.1309/AJCP7UHBFFFQDTV.
 69. Liu, X.C.; Bell, C.A.; Simmonds, K.A.; Russell, M.L.; Svenson, L.W. HPV Vaccine Utilization, Alberta 2008/09–2013/14 School Year. *BMC Infect Dis* 2016, 16, 15, doi:10.1186/s12879-016-1340-6.
 70. Forslund, O.; Miriam Elfström, K.; Lamin, H.; Dillner, J. HPV-mRNA and HPV-DNA Detection in Samples Taken up to Seven Years before Severe Dysplasia of Cervix Uteri. *Int J Cancer* 2019, 144, 1073–1081, doi:10.1002/ijc.31819.
 71. Matsukura, T.; Sugase, M. Human Papillomavirus Genomes in Squamous Cell Carcinomas of the Uterine Cervix. *Virology* 2004, 324, 439–449, doi:10.1016/j.virol.2004.03.017.
 72. Van Limbergen, E.J.; Dok, R.; Laenen, A.; Hauben, E.; Van den Weyngaert, D.; Voordeckers, M.; De Neve, W.; Duprez, F.; Nuyts, S. HPV-Related Oropharyngeal Cancers in Flanders (Belgium): A Multicenter Study. *B-ENT* 2014, 10, 7–14.
 73. Baalbergen, A.; Smedts, F.; Ewing, P.; Snijders, P.J.F.; Meijer, C.J.L.M.; Helmerhorst, T.J.M. HPV-Type Has No Impact on Survival of Patients with Adenocarcinoma of the Uterine Cervix. *Gynecol Oncol* 2013, 128, 530–534, doi:10.1016/j.ygyno.2012.12.013.
 74. Lin, S.-W.; Ghosh, A.; Porras, C.; Markt, S.C.; Rodriguez,

- A.C.; Schiffman, M.; Wacholder, S.; Kemp, T.J.; Pinto, L.A.; Gonzalez, P.; et al. HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. *PLoS One* 2013, 8, e53067, doi:10.1371/journal.pone.0053067.
75. Karube, A.; Sasaki, M.; Tanaka, H.; Nakagome, O.; Dahiya, R.; Fujimoto, S.; Tanaka, T. Human Papilloma Virus Type 16 Infection and the Early Onset of Cervical Cancer. *Biochem Biophys Res Commun* 2004, 323, 621–624, doi:10.1016/j.bbrc.2004.08.142.
76. Elmi, A.A.; Bansal, D.; Acharya, A.; Skariah, S.; Dargham, S.R.; Abu-Raddad, L.J.; Mohamed-Nady, N.; Amuna, P.; Al-Thani, A.A.J.; Sultan, A.A. Human Papillomavirus (HPV) Infection: Molecular Epidemiology, Genotyping, Seroprevalence and Associated Risk Factors among Arab Women in Qatar. *PLoS One* 2017, 12, e0169197, doi:10.1371/journal.pone.0169197.
77. Polansky, H.; Itzkovitz, E.; Javaherian, A. Human Papillomavirus (HPV): Systemic Treatment with Gene-Eden-VIR/Novirin Safely and Effectively Clears Virus. *Drug Des Devel Ther* 2017, 11, 575–583, doi:10.2147/DDDT.S123340.
78. Li, X.; Cao, X.; Li, Z.; Yang, Y.; Li, M.; Feng, B.; Xin, H.; Zhang, H.; Gao, L. Human Papillomavirus Awareness and Vaccine Acceptability among Men Who Have Sex with Men from Mainland China. *Sci Rep* 2019, 9, 8763, doi:10.1038/s41598-019-45258-0.
79. Park, J.S.; Chee, Y.H.; Namkoong, S.E.; Han, S.K.; Kim, T.E.; Lee, H.Y.; Kim, S.J. Human Papillomavirus Detection in Cervical Carcinoma Tissues and Para-aortic Lymph Nodes by the Polymerase Chain Reaction. *Gynecol Oncol* 1994, 53, 344–351, doi:10.1006/gyno.1994.1145.
80. Gaarenstroom, K.N.; Melkert, P.; Walboomers, J.M.M.; Van Den Brule, A.J.C.; Van Bommel, P.F.J.; Meyer, C.J.L.M.; Voorhorst, F.J.; Kenemans, P.; Helmerhorst, T.J.M. Human Papillomavirus DNA and Genotypes: Prognostic Factors for Progression of Cervical Intraepithelial Neoplasia. *Int J Gynecol Cancer* 1994, 4, 73–78, doi:10.1046/j.1525-1438.1994.04020073.x.
81. Palmer, E.; Newcombe, R.G.; Green, A.C.; Kelly, C.; Noel Gill, O.; Hall, G.; Fiander, A.N.; Pirotte, E.; Hibbitts, S.J.; Homer, J.; et al. Human Papillomavirus Infection Is Rare in Nonmalignant Tonsil Tissue in the UK: Implications for Tonsil Cancer Precursor Lesions. *Int J Cancer* 2014, 135, 2437–2443, doi:10.1002/ijc.28886.
82. Tachezy, R.; Smahelova, J.; Salakova, M.; Arbyn, M.; Rob, L.; Skapa, P.; Jirasek, T.; Hamsikova, E. Human Papillomavirus Genotype Distribution in Czech Women and Men with Diseases Etiologically Linked to HPV. *PLoS One* 2011, 6, e21913, doi:10.1371/journal.pone.0021913.
83. Chen, A.C.-H.; Waterboer, T.; Keleher, A.; Morrison, B.; Jindal, S.; McMillan, D.; Nicol, D.; Gardiner, R.A.; McMillan, N.A.J.; Antonsson, A. Human Papillomavirus in Benign Prostatic Hyperplasia and Prostatic Adenocarcinoma Patients. *Pathol Oncol Res* 2011, 17, 613–617, doi:10.1007/s12253-010-9357-4.
84. Ahmed, M.I.; Salahy, E.E.; Fayed, S.T.; El-Hefnawy, N.G.; Khalifa, A. Human Papillomavirus Infection among Egyptian Females with Cervical Carcinoma: Relationship to Spontaneous Apoptosis and TNF-Alpha. *Clin Biochem* 2001, 34, 491–498, doi:10.1016/s0009-9120(01)00243-0.
85. Wittawatmongkol, O.; Gatechompol, S.; Kerr, S.J.; Chalermchockcharoenkit, A.; Teeratakulpisarn, N.; Lermankul, W.; Thamkhantho, M.; Phanuphak, N.; Sohn, A.H.; Chokephabulkit, K.; et al. Human Papillomavirus Infection among Male Adolescents and Young Adults with Perinatally-Acquired HIV and without HIV in Thailand. *Int J STD AIDS* 2019, 30, 960–968, doi:10.1177/0956462419853384.
86. Jia, H.; Wang, X.; Long, Z.; Li, L. Human Papillomavirus Infection and Cervical Dysplasia in Female Sex Workers in Northeast China: An Observational Study. *BMC Public Health* 2015, 15, 695, doi:10.1186/s12889-015-2066-x.
87. Perino, A.; Giovannelli, L.; Schillaci, R.; Ruvolo, G.; Fiorentino, F.P.; Alimondi, P.; Cefalù, E.; Ammatuna, P. Human Papillomavirus Infection in Couples Undergoing in Vitro Fertilization Procedures: Impact on Reproductive Outcomes. *Fertil Steril* 2011, 95, 1845–1848, doi:10.1016/j.fertnstert.2010.11.047.
88. Bustos, D.A.; Grenón, M.S.; Benitez, M.; de Boccardo, G.; Pavan, J.V.; Gendelman, H. Human Papillomavirus Infection in Cyclosporin-Induced Gingival Overgrowth in Renal Allograft Recipients. *J Periodontol* 2001, 72, 741–744, doi:10.1902/jop.2001.72.6.741.
89. Weber, F.; Fuchs, P.G.; Pfister, H.J.; Hintner, H.; Fritsch, P.; Hoepfl, R. Human Papillomavirus Infection in Netherton's Syndrome. *Br J Dermatol* 2001, 144, 1044–1049, doi:10.1046/j.1365-2133.2001.04196.x.
90. Shibuski, C.H.; Lee, A.; Chen, H.; Webster-Cyriaque, J.; Seaman, T.; Landovitz, R.J.; John, M.; Reilly, N.; Naini, L.; Palefsky, J.; et al. Human Papillomavirus Infection in the Oral Cavity of HIV Patients Is Not Reduced by Initiating Antiretroviral Therapy. *AIDS* 2016, 30, 1573–1582, doi:10.1097/QAD.0000000000001072.
91. Sankaranarayanan, R.; Prabhu, P.R.; Pawlita, M.; Gheit, T.; Bhatla, N.; Muwonge, R.; Nene, B.M.; Esmy, P.O.; Joshi, S.; Poli, U.R.R.; et al. Immunogenicity and HPV Infection after One, Two, and Three Doses of Quadrivalent HPV Vaccine in Girls in India: A Multicentre Prospective Cohort Study. *Lancet Oncol* 2016, 17, 67–77, doi:10.1016/S1470-2045(15)00414-3.
92. Murray, M.L.; Meadows, J.; Doré, C.J.; Copas, A.J.; Haddow, L.J.; Lacey, C.; Jit, M.; Soldan, K.; Bennett, K.; Tetlow, M.; et al. Human Papillomavirus Infection: Protocol for a Randomised Controlled Trial of Imiquimod Cream (5%) versus Podophyllotoxin Cream (0.15%), in Combination with Quadrivalent Human Papillomavirus or Control Vaccination in the Treatment and Prevention of Recurrence of Anogenital Warts (HIPvac Trial). *BMC Med Res Methodol* 2018, 18, 125, doi:10.1186/s12874-018-0581-z.
93. Garland, S.M.; Insinga, R.P.; Sings, H.L.; Haupt, R.M.; Joura, E.A. Human Papillomavirus Infections and Vulvar Disease Development. *Cancer Epidemiol Biomarkers Prev* 2009, 18, 1777–1784, doi:10.1158/1055-9965.EPI-09-0067.
94. Ogura, K.; Ishii, K.; Matsumoto, T.; Kina, K.; Nojima, M.; Suda, K. Human Papillomavirus Localization in Cervical Adenocarcinoma and Adenosquamous Carcinoma Using In Situ Polymerase Chain Reaction: Review of the Literature of Human Papillomavirus Detection in These Carcinomas. *Pathol Int* 2006, 56, 301–308, doi:10.1111/j.1440-1827.2006.01964.x.
95. Lin, C.-C.; Hsieh, M.-C.; Hung, H.-C.; Tsao, S.-M.; Chen, S.-C.; Yang, H.-J.; Lee, Y.-T. Human Papillomavirus Prevalence and Behavioral Risk Factors among HIV-Infected and HIV-Uninfected Men Who Have Sex with Men in Taiwan. *Medicine (Baltimore)* 2018, 97, e13201, doi:10.1097/MD.00000000000013201.
96. AlObaid, A.; Al-Badawi, I.A.; Al-Kadri, H.; Gopala, K.; Kandeil, W.; Quint, W.; Al-Aker, M.; DeAntonio, R. Human Papillomavirus Prevalence and Type Distribution among Women Attending Routine Gynecological Examinations in Saudi Arabia. *BMC Infect Dis* 2014, 14, 643, doi:10.1186/s12879-014-0643-8.
97. Karunaratne, K.; Ihalagama, H.; Rohitha, S.; Molijn, A.; Gopala, K.; Schmidt, J.E.; Chen, J.; Datta, S.; Mehta, S. Human Papillomavirus Prevalence and Type-Distribution in Women with Cervical Lesions: A Cross-Sectional Study in Sri Lanka. *BMC Cancer* 2014, 14, 116, doi:10.1186/1471-2407-14-116.
98. Rathfisch, G.; Güngör, İ.; Uzun, E.; Keskin, Ö.; Tencere, Z. Human Papillomavirus Vaccines and Cervical Cancer: Awareness, Knowledge, and Risk Perception among Turkish Undergraduate Students. *J Cancer Educ* 2015, 30, 116–123, doi:10.1007/s13187-014-0703-1.
99. Naghashfar, Z.; Sawada, E.; Kutcher, M.J.; Swancar, J.; Gupta, J.; Daniel, R.; Kashima, H.; Woodruff, J.D.; Shah, K. Identification of Genital Tract Papillomaviruses HPV-6 and HPV-16 in Warts of the Oral Cavity. *J Med Virol* 1985, 17, 313–324, doi:10.1002/jmv.1890170404.
100. Partlová, S.; Bouček, J.; Kloudová, K.; Zábrodský, M.; Špíšek, R.; Fialová, A. (Immune System in Patients with Head and Neck Carcinoma). *Klin Onkol* 2015, 28 Suppl 4,

- 4S86-94, doi:10.14735/amko2015s86.
101. Roteli-Martins, C.M.; Naud, P.; De Borba, P.; Teixeira, J.C.; De Carvalho, N.S.; Zahaf, T.; Sanchez, N.; Geeraerts, B.; Descamps, D. Sustained Immunogenicity and Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine: Up to 8.4 Years of Follow-Up. *Hum Vaccin Immunother* 2012, **8**, 390–397, doi:10.4161/hv.18865.
 102. Gross, G.; Gissmann, L. (Urogenital and anal papillomavirus infections). *Hautarzt* 1986, **37**, 587–596.
 103. Williamson, A.L.; Brink, N.S.; Dehaeck, C.M.; Ovens, S.; Soeters, R.; Rybicki, E.P. Typing of Human Papillomaviruses in Cervical Carcinoma Biopsies from Cape Town. *J Med Virol* 1994, **43**, 231–237, doi:10.1002/jmv.1890430307.
 104. Mistry, N.; Simonsson, M.; Evander, M. Transcriptional Activation of the Human Papillomavirus Type 5 and 16 Long Control Region in Cells from Cutaneous and Mucosal Origin. *Virol J* 2007, **4**, 27, doi:10.1186/1743-422X-4-27.
 105. Inchingo, A.D.; Inchingo, A.M.; Bordea, I.R.; Xhajanka, E.; Romeo, D.M.; Romeo, M.; Zappone, C.M.F.; Malcangi, G.; Scarano, A.; Lorusso, F.; et al. The Effectiveness of Osseodensification Drilling Protocol for Implant Site Osteotomy: A Systematic Review of the Literature and Meta-Analysis. *Materials (Basel)* 2021, **14**, 1147, doi:10.3390/ma14051147.
 106. Marais, D.; Gawarecki, D.; Allan, B.; Ahmed, K.; Altini, L.; Cassim, N.; Gopolang, F.; Hoffman, M.; Ramjee, G.; Williamson, A.-L. The Effectiveness of Carraguard, a Vaginal Microbicide, in Protecting Women against High-Risk Human Papillomavirus Infection. *Antivir Ther* 2011, **16**, 1219–1226, doi:10.3851/IMP1890.
 107. Dhar, J.P.; Esselmacher, L.; Dhar, R.; Magee, A.; Ager, J.; Sokol, R.J. The Effect of History of Abnormal Pap Smear or Preceding HPV Infection on the Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus. *Hum Vaccin Immunother* 2018, **14**, 2318–2322, doi:10.1080/21645515.2018.1469592.
 108. Dipalma, G.; Inchingo, A.D.; Memè, L.; Casamassima, L.; Carone, C.; Malcangi, G.; Inchingo, F.; Palermo, A.; Inchingo, A.M. The Diagnosis and Management of Infraclosed Deciduous Molars: A Systematic Review. *Children (Basel)* 2024, **11**, 1375, doi:10.3390/children11111375.
 109. Lin, F.C.-F.; Huang, J.-Y.; Tsai, S.C.-S.; Nfor, O.N.; Chou, M.-C.; Wu, M.-F.; Lee, C.-T.; Jan, C.-F.; Liaw, Y.-P. The Association between Human Papillomavirus Infection and Female Lung Cancer: A Population-Based Cohort Study. *Medicine (Baltimore)* 2016, **95**, e3856, doi:10.1097/MD.0000000000003856.
 110. Hantz, S.; Decroisette, E.; Caly, H.; Renaudie, J.; Dussartre, C.; Bakeland, D.; Denis, F.; Alain, S. (Testing of a new probe 16/18/45 Hybrid Capture (Digene) in women with high risk HPV infection). *Pathol Biol (Paris)* 2009, **57**, 81–85, doi:10.1016/j.patbio.2008.08.002.
 111. Guo, X.; Qiu, L.; Wang, Y.; Wang, Y.; Meng, Y.; Zhu, Y.; Lu, L.; Jiang, S. Safety Evaluation of Chemically Modified Beta-Lactoglobulin Administered Intravaginally. *J Med Virol* 2016, **88**, 1098–1101, doi:10.1002/jmv.24439.
 112. GlaxoSmithKline Vaccine HPV-007 Study Group; Romanowski, B.; de Borba, P.C.; Naud, P.S.; Roteli-Martins, C.M.; De Carvalho, N.S.; Teixeira, J.C.; Aoki, F.; Ramjattan, B.; Shier, R.M.; et al. Sustained Efficacy and Immunogenicity of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine: Analysis of a Randomised Placebo-Controlled Trial up to 6.4 Years. *Lancet* 2009, **374**, 1975–1985, doi:10.1016/S0140-6736(09)61567-1.
 113. Shi, L.; Sanyal, G.; Ni, A.; Luo, Z.; Doshna, S.; Wang, B.; Graham, T.L.; Wang, N.; Volkin, D.B. Stabilization of Human Papillomavirus Virus-like Particles by Non-Ionic Surfactants. *J Pharm Sci* 2005, **94**, 1538–1551, doi:10.1002/jps.20377.
 114. Garolla, A.; Engl, B.; Pizzol, D.; Ghezzi, M.; Bertoldo, A.; Bottacin, A.; Noventa, M.; Foresta, C. Spontaneous Fertility and in Vitro Fertilization Outcome: New Evidence of Human Papillomavirus Sperm Infection. *Fertil Steril* 2016, **105**, 65–72.e1, doi:10.1016/j.fertnstert.2015.09.018.
 115. Zou, H.; Tabrizi, S.N.; Grulich, A.E.; Hocking, J.S.; Bradshaw, C.S.; Cornall, A.M.; Morrow, A.; Prestage, G.; Law, M.G.; Garland, S.M.; et al. Site-Specific Human Papillomavirus Infection in Adolescent Men Who Have Sex with Men (HYPER): An Observational Cohort Study. *Lancet Infect Dis* 2015, **15**, 65–73, doi:10.1016/S1473-3099(14)70994-6.
 116. Safaeian, M.; Hildesheim, A.; Gonzalez, P.; Yu, K.; Porras, C.; Li, Q.; Rodriguez, A.C.; Sherman, M.E.; Schiffman, M.; Wacholder, S.; et al. Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer. *PLoS One* 2012, **7**, e33619, doi:10.1371/journal.pone.0033619.
 117. Wei, F.; Su, Y.; Yao, X.; Cui, X.; Bian, L.; Yin, K.; Yu, X.; Zhuang, C.; Bi, Z.; Huang, S.; et al. Sex Differences in the Incidence and Clearance of Anal Human Papillomavirus Infection among Heterosexual Men and Women in Liuzhou, China: An Observational Cohort Study. *Int J Cancer* 2019, **145**, 807–816, doi:10.1002/ijc.32255.
 118. Soisson, A.P.; Reed, E.; Brown, P.; Ducatman, B.; Armistead, J.; Kennedy, S.; Wang, W.; Kramer, P.; Rose, S. Self-Test Device for Cytology and HPV Testing in Rural Appalachian Women: An Evaluation. *J Reprod Med* 2008, **53**, 441–448.
 119. Grandahl, M.; Rosenblad, A.; Stenhammar, C.; Tydén, T.; Westerling, R.; Larsson, M.; Oscarsson, M.; Andrae, B.; Dalianis, T.; Neveus, T. School-Based Intervention for the Prevention of HPV among Adolescents: A Cluster Randomised Controlled Study. *BMJ Open* 2016, **6**, e009875, doi:10.1136/bmjjopen-2015-009875.
 120. Hanna, G.J.; Lau, C.J.; Mahmood, U.; Supplee, J.G.; Mogili, A.R.; Haddad, R.I.; Jäne, P.A.; Paweletz, C.P. Salivary HPV DNA Informs Locoregional Disease Status in Advanced HPV-Associated Oropharyngeal Cancer. *Oral Oncol* 2019, **95**, 120–126, doi:10.1016/j.oraloncology.2019.06.019.
 121. Bisi-Onyemaechi, A.I.; Chikani, U.N.; Nduagubam, O. Reducing Incidence of Cervical Cancer: Knowledge and Attitudes of Caregivers in Nigerian City to Human Papilloma Virus Vaccination. *Infect Agent Cancer* 2018, **13**, 29, doi:10.1186/s13027-018-0202-9.
 122. Murata, S.; Takeuchi, Y.; Yamanaka, K.; Hayakawa, J.; Yoshida, M.; Yokokawa, R.; Wakana, A.; Sawata, M.; Tanaka, Y. Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: A Phase 3, Open-Label Study. *Jpn J Infect Dis* 2019, **72**, 299–305, doi:10.7883/yoken.JJID.2018.448.
 123. Denny, L.; Hendricks, B.; Gordon, C.; Thomas, F.; Hezareh, M.; Dobbelaere, K.; Durand, C.; Hervé, C.; Descamps, D. Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine in HIV-Positive Women in South Africa: A Partially-Blind Randomised Placebo-Controlled Study. *Vaccine* 2013, **31**, 5745–5753, doi:10.1016/j.vaccine.2013.09.032.
 124. Castellsagué, X.; Naud, P.; Chow, S.-N.; Wheeler, C.M.; Germar, M.J.V.; Lehtinen, M.; Paavonen, J.; Jaisamrarn, U.; Garland, S.M.; Salmerón, J.; et al. Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. *J Infect Dis* 2014, **210**, 517–534, doi:10.1093/infdis/jiu139.
 125. Safaeian, M.; Castellsagué, X.; Hildesheim, A.; Wacholder, S.; Schiffman, M.H.; Bozonnat, M.-C.; Baril, L.; Rosillon, D.; Costa Rica HPV Vaccine Trial and the PATRICIA study groups. Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. *J Infect Dis* 2018, **218**, 84–94, doi:10.1093/infdis/jiy112.
 126. Rositch, A.F.; Mao, L.; Hudgens, M.G.; Moses, S.; Agot, K.; Backes, D.M.; Nyagaya, E.; Snijders, P.J.F.; Meijer, C.J.L.M.; Bailey, R.C.; et al. Risk of HIV Acquisition among Circumcised and Uncircumcised Young Men with Penile Human Papillomavirus Infection. *AIDS* 2014, **28**, 745–752, doi:10.1097/QAD.0000000000000092.
 127. Hidalgo-Tenorio, C.; Gil-Anguita, C.; Ramírez-Taboada, J.;

- Esquivias, J.; López-Ruz, M.A.; Balgahata, O.M.; Javier-Martinez, R.; Pasquau, J. Risk Factors for Infection by Oncogenic Human Papillomaviruses in HIV-Positive MSM Patients in the ART Era (2010-2016). *Medicine (Baltimore)* 2017, 96, e8109, doi:10.1097/MD.00000000000008109.
128. Garcia, F.A.R.; Cornelison, T.; Nuño, T.; Greenspan, D.L.; Byron, J.W.; Hsu, C.-H.; Alberts, D.S.; Chow, H.-H.S. Results of a Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Women with Persistent High-Risk HPV Infection and Low-Grade Cervical Intraepithelial Neoplasia. *Gynecol Oncol* 2014, 132, 377–382, doi:10.1016/j.ygyno.2013.12.034.
129. Vitiello, F.; Tosco, V.; Monterubbiano, R.; Orilisi, G.; Gatto, M.L.; Sparabombe, S.; Memé, L.; Mengucci, P.; Putignano, A.; Orsini, G. Remineralization Efficacy of Four Remineralizing Agents on Artificial Enamel Lesions: SEM-EDS Investigation. *Materials (Basel)* 2022, 15, 4398, doi:10.3390/ma15134398.
130. Abate, A.; Cavagnetto, D.; Fama, A.; Maspero, C.; Farronato, G. Relationship between Breastfeeding and Malocclusion: A Systematic Review of the Literature. *Nutrients* 2020, 12, 3688, doi:10.3390/nu12123688.
131. Villagómez-Ortíz, V.J.; Paz-Delgadillo, D.E.; Marino-Martínez, I.; Ceseñas-Falcón, L.A.; Sandoval-de la Fuente, A.; Reyes-Escobedo, A. (Prevalence of human papillomavirus infection in squamous cell carcinoma of the oral cavity, oropharynx and larynx). *Cir Cir* 2016, 84, 363–368, doi:10.1016/j.circir.2016.01.006.
132. Yang, Y.; Meng, Y.-L.; Duan, S.-M.; Zhan, S.-B.; Guan, R.-L.; Yue, T.-F.; Kong, L.-H.; Zhou, L.; Deng, L.-H.; Huang, C.; et al. REBACIN® as a Noninvasive Clinical Intervention for High-Risk Human Papillomavirus Persistent Infection. *Int J Cancer* 2019, 145, 2712–2719, doi:10.1002/ijc.32344.
133. Mane, A.; Sahasrabuddhe, V.V.; Nirmalkar, A.; Risbud, A.R.; Sahay, S.; Bhosale, R.A.; Vermund, S.H.; Mehendale, S.M. Rates and Determinants of Incidence and Clearance of Cervical HPV Genotypes among HIV-Seropositive Women in Pune, India. *J Clin Virol* 2017, 88, 26–32, doi:10.1016/j.jcv.2016.10.013.
134. Inchingolo, A.D.; Ferrara, I.; Viapiano, F.; Netti, A.; Campanelli, M.; Buongiorno, S.; Latini, G.; Carpentiere, V.; Ciocia, A.M.; Ceci, S.; et al. Rapid Maxillary Expansion on the Adolescent Patient: Systematic Review and Case Report. *Children (Basel)* 2022, 9, 1046, doi:10.3390/children9071046.
135. Zhao, H.; Feng, X.-L.; Zhao, Y.; Li, N. (Randomized controlled study: Sophora flavescens gel in treatment of cervical HPV infection). *Zhongguo Zhong Yao Za Zhi* 2016, 41, 4072–4075, doi:10.4268/cjcmmm20162129.
136. Colombara, D.V.; Manhart, L.E.; Carter, J.J.; Hawes, S.E.; Weiss, N.S.; Hughes, J.P.; Barnett, M.J.; Goodman, G.E.; Smith, J.S.; Qiao, Y.-L.; et al. Prior Human Polyomavirus and Papillomavirus Infection and Incident Lung Cancer: A Nested Case-Control Study. *Cancer Causes Control* 2015, 26, 1835–1844, doi:10.1007/s10552-015-0676-3.
137. Zhang, Z.; Zhang, D.; Xiao, B.B.; Zhang, R.; Bai, H.H.; Dong, H.Y.; Bi, H.; Liu, Z.H. (Primary study on the relationship between high-risk HPV infection and vaginal cervical microbiota). *Zhonghua Fu Chan Ke Za Zhi* 2018, 53, 471–480, doi:10.3760/cma.j.issn.0529-567x.2018.07.006.
138. Sargent, A.; Bailey, A.; Almonte, M.; Turner, A.; Thomson, C.; Petro, J.; Desai, M.; Mather, J.; Moss, S.; Roberts, C.; et al. Prevalence of Type-Specific HPV Infection by Age and Grade of Cervical Cytology: Data from the ARTISTIC Trial. *Br J Cancer* 2008, 98, 1704–1709, doi:10.1038/sj.bjc.6604324.
139. Lucas-Roxburgh, R.; Benschop, J.; Dunowska, M.; Perrott, M. Prevalence of Human Papillomaviruses in the Mouths of New Zealand Women. *N Z Med J* 2015, 128, 45–52.
140. Shin, H.-R.; Lee, D.-H.; Herrero, R.; Smith, J.S.; Vaccarella, S.; Hong, S.-H.; Jung, K.-Y.; Kim, H.-H.; Park, U.-D.; Cha, H.-S.; et al. Prevalence of Human Papillomavirus Infection in Women in Busan, South Korea. *Int J Cancer* 2003, 103, 413–421, doi:10.1002/ijc.10825.
141. Kulkarni, S.S.; Kulkarni, S.S.; Vastrad, P.P.; Kulkarni, B.B.; Markande, A.R.; Kadakol, G.S.; Hiremath, S.V.; Kaliwal, S.; Patil, B.R.; Gai, P.B. Prevalence and Distribution of High Risk Human Papillomavirus (HPV) Types 16 and 18 in Carcinoma of Cervix, Saliva of Patients with Oral Squamous Cell Carcinoma and in the General Population in Karnataka, India. *Asian Pac J Cancer Prev* 2011, 12, 645–648.
142. Li, Z.; Liu, F.; Cheng, S.; Shi, L.; Yan, Z.; Yang, J.; Shi, L.; Yao, Y.; Ma, Y. Prevalence of HPV Infection among 28,457 Chinese Women in Yunnan Province, Southwest China. *Sci Rep* 2016, 6, 21039, doi:10.1038/srep21039.
143. Borg, A.J.; Medley, G.; Garland, S.M. Prevalence of HPV in a Melbourne Female STD Population: Comparison of RNA and DNA Probes in Detecting HPV by Dot Blot Hybridization. *Int J STD AIDS* 1993, 4, 159–164, doi:10.1177/095646249300400307.
144. da Costa, A.M.; Fregnani, J.H.T.G.; Pastrez, P.R.A.; Mariano, V.S.; Neto, C.S.; Guimarães, D.P.; de Oliveira, K.M.G.; Neto, S.A.Z.; Nunes, E.M.; Ferreira, S.; et al. Prevalence of High Risk HPV DNA in Esophagus Is High in Brazil but Not Related to Esophageal Squamous Cell Carcinoma. *Histol Histopathol* 2018, 33, 357–363, doi:10.14670/HH-11-929.
145. Thorsteinsson, K.; Støgaard, M.; Katzenstein, T.L.; Ladelund, S.; Rönsholt, F.F.; Johansen, I.S.; Pedersen, G.; Gaardsting, A.; Nielsen, L.N.; Bonde, J.; et al. Prevalence of Cervical, Oral, and Anal Human Papillomavirus Infection in Women Living with HIV in Denmark - The SHADE Cohort Study. *J Clin Virol* 2018, 105, 64–71, doi:10.1016/j.jcv.2018.05.010.
146. Vu, L.T.H.; Bui, D. Prevalence of Cervical Human Papilloma Virus Infection among Married Women in Vietnam, 2011. *Asian Pac J Cancer Prev* 2012, 13, 37–40, doi:10.7314/apjc.2012.13.1.037.
147. Szabó, E.; Kósá, C.; Babarczi, E.; Sulyok, M.; Ujhelyi, E.; Báñegyi, D.; Vályi-Nagy, I. Prevalence of Anal Human Papillomavirus Infection in Hungarian Men Who Have Sex with Men. *Pathol Oncol Res* 2018, 24, 671–677, doi:10.1007/s12253-017-0292-5.
148. Nagata, N.; Watanabe, K.; Nishijima, T.; Tadokoro, K.; Watanabe, K.; Shimbo, T.; Niikura, R.; Sekine, K.; Akiyama, J.; Teruya, K.; et al. Prevalence of Anal Human Papillomavirus Infection and Risk Factors among HIV-Positive Patients in Tokyo, Japan. *PLoS One* 2015, 10, e0137434, doi:10.1371/journal.pone.0137434.
149. Tan, S.C.; Ismail, M.P.; Duski, D.R.; Othman, N.H.; Ankathil, R. Prevalence and Type Distribution of Human Papillomavirus (HPV) in Malaysian Women with and without Cervical Cancer: An Updated Estimate. *Biosci Rep* 2018, 38, BSR20171268, doi:10.1042/BSR20171268.
150. Roset Bahmanyar, E.; Paavonen, J.; Naud, P.; Salmerón, J.; Chow, S.-N.; Apter, D.; Kitchener, H.; Castellsagué, X.; Teixeira, J.C.; Skinner, S.R.; et al. Prevalence and Risk Factors for Cervical HPV Infection and Abnormalities in Young Adult Women at Enrolment in the Multinational PATRICIA Trial. *Gynecol Oncol* 2012, 127, 440–450, doi:10.1016/j.ygyno.2012.08.033.
151. Balzanelli, M.G.; Distratis, P.; Aityan, S.K.; Amatulli, F.; Catucci, O.; Cefalo, A.; De Michele, A.; Dipalma, G.; Inchingolo, F.; Lazzaro, R.; et al. An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology. *Endocr Metab Immune Disord Drug Targets* 2022, 22, 1–5, doi:10.2174/187153032166210127141945.
152. Sartori, M.P.D.N.; Agostini, L.P.; Tovar, T.T.; Reis, R.S.; Dettogno, R.S.; Dos Santos, E. de V.W.; Filho, A.C.; Louro, I.D. Presence of Infection and Analysis of HPV Subtypes in Girls Younger than 9 Years Old Attended at a Referral Service in Espírito Santo, Brazil. *J Med Virol* 2018, 90, 761–766, doi:10.1002/jmv.24992.
153. Mariaggi, A.-A.; Pérez, H.; Perrier, M.; Visseaux, B.; Collin, G.; Veyre, D.; Le Hingrat, Q.; Ferré, V.M.; Joly, V.; Couvelard, A.; et al. Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58. *J Infect Dis* 2018, 218, 1027–1036, doi:10.1093/infdis/jiy287.

154. Lukaszuk, K.; Liss, J.; Gulczynski, J.; Nowaczyk, M.; Nakonieczny, M.; Piatkowski, M.; Sliwinski, W.; Baay, M.; Woźniak, I.; Maj, B.; et al. Predictive Value of HPV DNA in Lymph Nodes in Surgically Treated Cervical Carcinoma Patients--a Prospective Study. *Gynecol Oncol* 2007, 104, 721–726, doi:10.1016/j.ygyno.2006.10.018.
155. Al-Naggar, R.A.; Bobryshev, Y.V.; Al-Jashamy, K.; Al-Musli, M. Practice of HPV Vaccine and Associated Factors among School Girls in Melaka, Malaysia. *Asian Pac J Cancer Prev* 2012, 13, 3835–3840, doi:10.7314/apjcp.2012.13.8.3835.
156. Struyf, F.; Colau, B.; Wheeler, C.M.; Naud, P.; Garland, S.; Quint, W.; Chow, S.-N.; Salmerón, J.; Lehtinen, M.; Del Rosario-Raymundo, M.R.; et al. Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA. *Clin Vaccine Immunol* 2015, 22, 235–244, doi:10.1128/CVI.00457-14.
157. Wells, L. a. R.; Junor, E.J.; Conn, B.; Pattle, S.; Cuschieri, K. Population-Based P16 and HPV Positivity Rates in Oropharyngeal Cancer in Southeast Scotland. *J Clin Pathol* 2015, 68, 849–852, doi:10.1136/jclinpath-2015-202947.
158. Schwarz, T.F.; Spaczynski, M.; Schneider, A.; Wysocki, J.; Galaj, A.; Schulze, K.; Poncelet, S.M.; Catteau, G.; Thomas, F.; Descamps, D. Persistence of Immune Response to HPV-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Women Aged 15–55 Years. *Hum Vaccin* 2011, 7, 958–965, doi:10.4161/hv.7.9.15999.
159. Ramanakumar, A.V.; Naud, P.; Roteli-Martins, C.M.; de Carvalho, N.S.; de Borba, P.C.; Teixeira, J.C.; Blatter, M.; Moscicki, A.-B.; Harper, D.M.; Romanowski, B.; et al. Incidence and Duration of Type-Specific Human Papillomavirus Infection in High-Risk HPV-Naïve Women: Results from the Control Arm of a Phase II HPV-16/18 Vaccine Trial. *BMJ Open* 2016, 6, e011371, doi:10.1136/bmjopen-2016-011371.
160. Harper, D.M. Impact of Vaccination with Cervarix (Trade Mark) on Subsequent HPV-16/18 Infection and Cervical Disease in Women 15–25 Years of Age. *Gynecol Oncol* 2008, 110, S11–17, doi:10.1016/j.ygyno.2008.06.029.
161. Cheng, S.-H.; Liao, K.-S.; Wang, C.-C.; Cheng, C.-Y.; Chu, F.-Y. Multiple Types of Human Papillomavirus Infection and Anal Precancerous Lesions in HIV-Infected Men in Taiwan: A Cross-Sectional Study. *BMJ Open* 2018, 8, e019894, doi:10.1136/bmjopen-2017-019894.
162. Giuliano, A.R.; Joura, E.A.; Garland, S.M.; Huh, W.K.; Iversen, O.-E.; Kjaer, S.K.; Ferenczy, A.; Kurman, R.J.; Ronnett, B.M.; Stoler, M.H.; et al. Nine-Valent HPV Vaccine Efficacy against Related Diseases and Definitive Therapy: Comparison with Historic Placebo Population. *Gynecol Oncol* 2019, 154, 110–117, doi:10.1016/j.ygyno.2019.03.253.
163. Sasagawa, T.; Rose, R.C.; Azar, K.K.; Sakai, A.; Inoue, M. Mucosal Immunoglobulin-A and -G Responses to Oncogenic Human Papilloma Virus Capsids. *Int J Cancer* 2003, 104, 328–335, doi:10.1002/ijc.10939.
164. Alder, S.; Gustafsson, S.; Perinetti, C.; Mints, M.; Sundström, K.; Andersson, S. Mothers' Acceptance of Human Papillomavirus (HPV) Vaccination for Daughters in a Country with a High Prevalence of HPV. *Oncol Rep* 2015, 33, 2521–2528, doi:10.3892/or.2015.3817.
165. Inchingolo, F.; Tatullo, M.; Abenavoli, F.M.; Marrelli, M.; Inchingolo, A.D.; Servili, A.; Inchingolo, A.M.; Dipalma, G. A Hypothetical Correlation between Hyaluronic Acid Gel and Development of Cutaneous Metaplastic Synovial Cyst. *Head Face Med* 2010, 6, 13, doi:10.1186/1746-160X-6-13.
166. Bavetta, G.; Bavetta, G.; Randazzo, V.; Cavataio, A.; Paderni, C.; Grassia, V.; Dipalma, G.; Gargiulo Isacco, C.; Scarano, A.; De Vito, D.; et al. A Retrospective Study on Insertion Torque and Implant Stability Quotient (ISQ) as Stability Parameters for Immediate Loading of Implants in Fresh Extraction Sockets. *Biomed Res Int* 2019, 2019, 9720419, doi:10.1155/2019/9720419.
167. Marinelli, G.; Inchingolo, A.D.; Inchingolo, A.M.; Malcangi, G.; Limongelli, L.; Montenegro, V.; Coloccia, G.; Laudadio, C.; Patano, A.; Inchingolo, F.; et al. White Spot Lesions in Orthodontics: Prevention and Treatment. A Descriptive Review. *J Biol Regul Homeost Agents* 2021, 35, 227–240, doi:10.23812/21-2supp1-24.
168. Malcangi, G.; Patano, A.; Ciocia, A.M.; Netti, A.; Viapiano, F.; Palumbo, I.; Trilli, I.; Guglielmo, M.; Inchingolo, A.D.; Dipalma, G.; et al. Benefits of Natural Antioxidants on Oral Health. *Antioxidants (Basel)* 2023, 12, 1309, doi:10.3390/antiox12061309.
169. Scarano, A.; Khater, A.G.A.; Gehrke, S.A.; Serra, P.; Francesco, I.; Di Carmine, M.; Tari, S.R.; Leo, L.; Lorusso, F. Current Status of Peri-Implant Diseases: A Clinical Review for Evidence-Based Decision Making. *J Funct Biomater* 2023, 14, 210, doi:10.3390/jfb14040210.
170. Romita, P.; Foti, C.; Calogiuri, G.; Cantore, S.; Ballini, A.; Dipalma, G.; Inchingolo, F. Contact Dermatitis Due to Transdermal Therapeutic Systems: A Clinical Update. *Acta Biomed* 2018, 90, 5–10, doi:10.23750/abm.v90i1.6563.
171. Scarano, A.; Inchingolo, F.; Lorusso, F. Environmental Disinfection of a Dental Clinic during the Covid-19 Pandemic: A Narrative Insight. *Biomed Res Int* 2020, 2020, 8896812, doi:10.1155/2020/8896812.
172. Balzanelli, M.G.; Distratis, P.; Catucci, O.; Cefalo, A.; Lazzaro, R.; Inchingolo, F.; Tomassone, D.; Aityan, S.K.; Ballini, A.; Nguyen, K.C.D.; et al. Mesenchymal Stem Cells: The Secret Children's Weapons against the SARS-CoV-2 Lethal Infection. *Applied Sciences* 2021, 11, 1696, doi:10.3390/app11041696.
173. Inchingolo, F.; Tatullo, M.; Abenavoli, F.M.; Marrelli, M.; Inchingolo, A.D.; Corelli, R.; Inchingolo, A.M.; Dipalma, G. Upper Eyelid Reconstruction: A Short Report of an Eyelid Defect Following a Thermal Burn. *Head Face Med* 2009, 5, 26, doi:10.1186/1746-160X-5-26.
174. Corriero, A.; Gadaleta, R.M.; Puntillo, F.; Inchingolo, F.; Moschetta, A.; Brienza, N. The Central Role of the Gut in Intensive Care. *Crit Care* 2022, 26, 379, doi:10.1186/s13054-022-04259-8.
175. Inchingolo, F.; Tatullo, M.; Pacifici, A.; Gargari, M.; Inchingolo, A.D.; Inchingolo, A.M.; Dipalma, G.; Marrelli, M.; Abenavoli, F.M.; Pacifici, L. Use of Dermal-Fat Grafts in the Post-Oncological Reconstructive Surgery of Atrophies in the Zygomatic Region: Clinical Evaluations in the Patients Undergone to Previous Radiation Therapy. *Head Face Med* 2012, 8, 33, doi:10.1186/1746-160X-8-33.
176. Inchingolo, A.D.; Patano, A.; Coloccia, G.; Ceci, S.; Inchingolo, A.M.; Marinelli, G.; Malcangi, G.; Di Pede, C.; Garibaldi, M.; Ciocia, A.M.; et al. Treatment of Class III Malocclusion and Anterior Crossbite with Aligners: A Case Report. *Medicina (Kaunas)* 2022, 58, 603, doi:10.3390/medicina58050603.
177. Inchingolo, A.M.; Malcangi, G.; Costa, S.; Fatone, M.C.; Avantario, P.; Campanelli, M.; Piras, F.; Patano, A.; Ferrara, I.; Di Pede, C.; et al. Tooth Complications after Orthodontic Miniscrews Insertion. *Int J Environ Res Public Health* 2023, 20, 1562, doi:10.3390/ijerph2021562.
178. Laforgia, A.; Inchingolo, A.D.; Piras, F.; Colonna, V.; Giorgio, R.V.; Carone, C.; Rapone, B.; Malcangi, G.; Inchingolo, A.M.; Inchingolo, F.; et al. Therapeutic Strategies and Genetic Implications for Periodontal Disease Management: A Systematic Review. *Int J Mol Sci* 2024, 25, 7217, doi:10.3390/ijms25137217.
179. Inchingolo, F.; Inchingolo, A.D.; Latini, G.; Trilli, I.; Ferrante, L.; Nardelli, P.; Malcangi, G.; Inchingolo, A.M.; Mancini, A.; Palermo, A.; et al. The Role of Curcumin in Oral Health and Diseases: A Systematic Review. *Antioxidants (Basel)* 2024, 13, 660, doi:10.3390/antiox13060660.
180. Santacroce, L.; Sardaro, N.; Topi, S.; Pettini, F.; Bottalico, L.; Cantore, S.; Casella, G.; Del Prete, R.; Dipalma, G.; Inchingolo, F. The Pivotal Role of Oral Microbiota in Health and Disease. *J Biol Regul Homeost Agents* 2020, 34, 733–737, doi:10.23812/20-127-L-45.
181. Inchingolo, A.D.; Cazzolla, A.P.; Di Cosola, M.; Greco Lucchina, A.; Santacroce, L.; Charitos, I.A.; Topi, S.; Malcangi, G.; Hazballa, D.; Scarano, A.; et al. The Integumentary System and Its Microbiota between Health and Disease. *J Biol Regul Homeost Agents* 2021, 35, 303–321, doi:10.23812/21-2supp1-30.

182. Inchingo, A.D.; Patano, A.; Coloccia, G.; Ceci, S.; Inchingo, A.M.; Marinelli, G.; Malcangi, G.; Montenegro, V.; Laudadio, C.; Pede, C.D.; et al. The Efficacy of a New AMCOP® Elastodontic Protocol for Orthodontic Interceptive Treatment: A Case Series and Literature Overview. *Int J Environ Res Public Health* 2022, 19, 988, doi:10.3390/ijerph19020988.
183. Inchingo, A.D.; Inchingo, A.M.; Bordea, I.R.; Xhajanka, E.; Romeo, D.M.; Romeo, M.; Zappone, C.M.F.; Malcangi, G.; Scarano, A.; Lorusso, F.; et al. The Effectiveness of Osseodensification Drilling Protocol for Implant Site Osteotomy: A Systematic Review of the Literature and Meta-Analysis. *Materials (Basel)* 2021, 14, 1147, doi:10.3390/ma14051147.
184. Dipalma, G.; Inchingo, A.D.; Memè, L.; Casamassima, L.; Carone, C.; Malcangi, G.; Inchingo, F.; Palermo, A.; Inchingo, A.M. The Diagnosis and Management of Infraclosed Deciduous Molars: A Systematic Review. *Children (Basel)* 2024, 11, 1375, doi:10.3390/children1111375.
185. Inchingo, A.M.; Fatone, M.C.; Malcangi, G.; Avantario, P.; Piras, F.; Patano, A.; Di Pede, C.; Netti, A.; Ciocia, A.M.; De Rivo, E.; et al. Modifiable Risk Factors of Non-Syndromic Orofacial Clefts: A Systematic Review. *Children (Basel)* 2022, 9, 1846, doi:10.3390/children9121846.
186. Inchingo, A.D.; Dipalma, G.; Inchingo, A.M.; Malcangi, G.; Santacroce, L.; D'Oría, M.T.; Isacco, C.G.; Bordea, I.R.; Candrea, S.; Scarano, A.; et al. The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. *Antioxidants (Basel)* 2021, 10, 881, doi:10.3390/antiox10060881.
187. Lorusso, F.; Inchingo, F.; Dipalma, G.; Postiglione, F.; Fulle, S.; Scarano, A. Synthetic Scaffold/Dental Pulp Stem Cell (DPSC) Tissue Engineering Constructs for Bone Defect Treatment: An Animal Studies Literature Review. *Int J Mol Sci* 2020, 21, 9765, doi:10.3390/ijms21249765.
188. Inchingo, A.M.; Malcangi, G.; Ferrante, L.; Del Vecchio, G.; Viapiano, F.; Inchingo, A.D.; Mancini, A.; Annicchiarico, C.; Inchingo, F.; Dipalma, G.; et al. Surface Coatings of Dental Implants: A Review. *J Funct Biomater* 2023, 14, 287, doi:10.3390/jfb14050287.
189. Inchingo, F.; Cantore, S.; Dipalma, G.; Georgakopoulos, I.; Almasri, M.; Gheno, E.; Motta, A.; Marrelli, M.; Farronato, D.; Ballini, A.; et al. Platelet Rich Fibrin in the Management of Medication-Related Osteonecrosis of the Jaw: A Clinical and Histopathological Evaluation. *J Biol Regul Homeost Agents* 2017, 31, 811–816.
190. Scarano, A.; Inchingo, F.; Rapone, B.; Lucchina, A.G.; Qorri, E.; Lorusso, F. Role of Autologous Platelet Gel (APG) in Bone Healing: A Rabbit Study. *Applied Sciences* 2021, 11, 395, doi:10.3390/app11010395.
191. Contaldo, M.; Boccellino, M.; Zannini, G.; Romano, A.; Sciarra, A.; Sacco, A.; Settembre, G.; Coppola, M.; Di Carlo, A.; D'Angelo, L.; et al. Sex Hormones and Inflammation Role in Oral Cancer Progression: A Molecular and Biological Point of View. *J Oncol* 2020, 2020, 9587971, doi:10.1155/2020/9587971.
192. Inchingo, F.; Tatullo, M.; Abenavoli, F.M.; Marrelli, M.; Inchingo, A.D.; Villabruna, B.; Inchingo, A.M.; Dipalma, G. Severe Anisocoria after Oral Surgery under General Anesthesia. *Int J Med Sci* 2010, 7, 314–318, doi:10.7150/ijms.7.314.
193. Farì, G.; Megna, M.; Scacco, S.; Ranieri, M.; Raele, M.V.; Chiaia Noya, E.; Macchiarola, D.; Bianchi, F.P.; Carati, D.; Panico, S.; et al. Hemp Seed Oil in Association with β -Caryophyllene, Myrcene and Ginger Extract as a Nutraceutical Integration in Knee Osteoarthritis: A Double-Blind Prospective Case-Control Study. *Medicina (Kaunas)* 2023, 59, 191, doi:10.3390/medicina59020191.
194. Goldoni, R.; Scolaro, A.; Boccalari, E.; Dolci, C.; Scarano, A.; Inchingo, F.; Ravazzani, P.; Muti, P.; Tartaglia, G. Malignancies and Biosensors: A Focus on Oral Cancer Detection through Salivary Biomarkers. *Biosensors (Basel)* 2021, 11, 396, doi:10.3390/bios11100396.
195. Scarano, A.; Rapone, B.; Amuso, D.; Inchingo, F.; Lorusso, F. Hyaluronic Acid Fillers Enriched with Glycine and Proline in Eyebrow Augmentation Procedure. *Aesthetic Plast Surg* 2022, 46, 419–428, doi:10.1007/s00266-021-02412-2.
196. Grassi, F.R.; Ciccolella, F.; D'Apolito, G.; Papa, F.; Iuso, A.; Salzo, A.E.; Trentadue, R.; Nardi, G.M.; Scivetti, M.; De Matteo, M.; et al. Effect of Low-Level Laser Irradiation on Osteoblast Proliferation and Bone Formation. *J Biol Regul Homeost Agents* 2011, 25, 603–614.
197. Inchingo, F.; Inchingo, A.D.; Palumbo, I.; Guglielmo, M.; Balestrieri, L.; Casamassima, L.; Ciccarese, D.; Marotti, P.; Mancini, A.; Palermo, A.; et al. Management of Physiological Gingival Melanosis by Diode Laser Depigmentation versus Surgical Scalpel: A Systematic Review. *Dentistry Review* 2024, 4, 100146, doi:10.1016/j.dentre.2024.100146.
198. Signorini, L.; Ballini, A.; Arrigoni, R.; De Leonardi, F.; Saini, R.; Cantore, S.; De Vito, D.; Coscia, M.F.; Dipalma, G.; Santacroce, L.; et al. Evaluation of a Nutraceutical Product with Probiotics, Vitamin D, Plus Banaba Leaf Extracts (Lagerstroemia Speciosa) in Glycemic Control. *Endocr Metab Immune Disord Drug Targets* 2021, 21, 1356–1365, doi:10.2174/187153032066201109115415.
199. Mummolo, S.; Marchetti, E.; Di Martino, S.; Scorzetti, L.; Marzo, G. Aggressive Periodontitis: Laser Nd:YAG Treatment versus Conventional Surgical Therapy. *Eur J Paediatr Dent* 2008, 9, 88–92.
200. Romasco, T.; Tumedei, M.; Inchingo, F.; Pignatelli, P.; Montesani, L.; Iezzi, G.; Petrini, M.; Piattelli, A.; Di Pietro, N. A Narrative Review on the Effectiveness of Bone Regeneration Procedures with OsteoBiol® Collagenated Porcine Grafts: The Translational Research Experience over 20 Years. *J Funct Biomater* 2022, 13, 121, doi:10.3390/jfb13030121.
201. Arrigoni, R.; Ballini, A.; Santacroce, L.; Cantore, S.; Inchingo, A.; Inchingo, F.; Di Domenico, M.; Quagliuolo, L.; Boccellino, M. Another Look at Dietary Polyphenols: Challenges in Cancer Prevention and Treatment. *Curr Med Chem* 2022, 29, 1061–1082, doi:10.2174/092986732866210810154732.
202. Balzanelli, M.G.; Distratis, P.; Aityan, S.K.; Amatulli, F.; Catucci, O.; Cefalo, A.; De Michele, A.; Dipalma, G.; Inchingo, F.; Lazzaro, R.; et al. An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology. *Endocr Metab Immune Disord Drug Targets* 2022, 22, 1–5, doi:10.2174/187153032166210127141945.
203. Esperouz, F.; Caponio, V.C.A.; Santarelli, A.; Ballini, A.; Lo Muzio, L.; Ciavarella, D.; Lo Russo, L. Are We Ready to Use Ultrasounds in the Clinical Assessment of Depth of Invasion and Tumor Thickness in Oral Squamous Cell Carcinoma? Results from a Systematic Review, Meta-Analysis and Trial Sequential Analysis. *Oral Oncol* 2024, 159, 107104, doi:10.1016/j.oraloncology.2024.107104.
204. Pennazza, G.; Marchetti, E.; Santonico, M.; Mantini, G.; Mummolo, S.; Marzo, G.; Paolesse, R.; D'Amico, A.; Di Natale, C. Application of a Quartz Microbalance Based Gas Sensor Array for the Study of Halitosis. *J Breath Res* 2008, 2, 017009, doi:10.1088/1752-7155/2/1/017009.
205. Memè, L.; Notarstefano, V.; Sampalmieri, F.; Orilisi, G.; Quinzi, V. ATR-FTIR Analysis of Orthodontic Invisalign® Aligners Subjected to Various In Vitro Aging Treatments. *Materials (Basel)* 2021, 14, 818, doi:10.3390/ma14040818.
206. Vimercati, L.; De Maria, L.; Quarato, M.; Caputi, A.; Gesualdo, L.; Migliore, G.; Cavone, D.; Sponselli, S.; Pipoli, A.; Inchingo, F.; et al. Association between Long COVID and Overweight/Obesity. *J Clin Med* 2021, 10, 4143, doi:10.3390/jcm10184143.
207. Maspero, C.; Prevedello, C.; Giannini, L.; Galbiati, G.; Farronato, G. Atypical Swallowing: A Review. *Minerva Stomatol* 2014, 63, 217–227.
208. Inchingo, F.; Vermesan, D.; Inchingo, A.D.; Malcangi, G.; Santacroce, L.; Scacco, S.; Benagiano, V.; Girolamo, F.; Cagiano, R.; Caprio, M.; et al. Bedsores Successfully Treated with Topical Phenytoin. *Acta Biomed* 2017, 88, 45–48, doi:10.23750/abm.v88i1.5794.
209. Gasparro, R.; Pucci, M.; Costanzo, E.; Urzì, O.; Tinnirello, V.; Moschetti, M.; Conigliaro, A.; Raimondo, S.; Corleone, V.; Fontana, S.; et al. Citral-Enriched Fraction of Lemon

- Essential Oil Mitigates LPS-Induced Hepatocyte Injuries. *Biology* (Basel) 2023, 12, 1535, doi:10.3390/biology12121535.
210. Inchingo, A.D.; Malcangi, G.; Inchingo, A.M.; Piras, F.; Settanni, V.; Garofoli, G.; Palmieri, G.; Ceci, S.; Patano, A.; De Leonardi, N.; et al. Benefits and Implications of Resveratrol Supplementation on Microbiota Modulations: A Systematic Review of the Literature. *Int J Mol Sci* 2022, 23, 4027, doi:10.3390/ijms23074027.
211. Bambini, F.; Orilisi, G.; Quaranta, A.; Memè, L. Biological Oriented Immediate Loading: A New Mathematical Implant Vertical Insertion Protocol, Five-Year Follow-Up Study. *Materials* (Basel) 2021, 14, 387, doi:10.3390/ma14020387.
212. Di Cosola, M.; Cazzolla, A.P.; Charitos, I.A.; Ballini, A.; Inchingo, F.; Santacroce, L. Candida Albicans and Oral Carcinogenesis. A Brief Review. *J Fungi* (Basel) 2021, 7, 476, doi:10.3390/jof7060476.
213. Teja, K.V.; Janani, K.; Srivastava, K.C.; Shrivastava, D.; Natoli, V.; Di Blasio, M.; Cicciù, M.; Minervini, G. Comparative Evaluation of Antimicrobial Efficacy of Different Combinations of Calcium Hydroxide against Enterococcus Faecalis. *BMC Oral Health* 2023, 23, 849, doi:10.1186/s12903-023-03552-4.
214. Farronato, G.; Cannalire, P.; Martinelli, G.; Tubertini, I.; Giannini, L.; Galbiati, G.; Maspero, C. Cleft Lip and/or Palate: Review. *Minerva Stomatol* 2014, 63, 111–126.
215. Romita, P.; Foti, C.; Caloguri, G.; Cantore, S.; Ballini, A.; Dipalma, G.; Inchingo, F. Contact Dermatitis Due to Transdermal Therapeutic Systems: A Clinical Update. *Acta Biomed* 2018, 90, 5–10, doi:10.23750/abm.v90i1.6563.
216. Bordea, I.R.; Xhajanka, E.; Candrea, S.; Bran, S.; Onișor, F.; Inchingo, A.D.; Malcangi, G.; Pham, V.H.; Inchingo, A.M.; Scarano, A.; et al. Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. *Microorganisms* 2020, 8, 1704, doi:10.3390/microorganisms8111704.
217. Malcangi, G.; Inchingo, A.D.; Inchingo, A.M.; Santacroce, L.; Marinelli, G.; Mancini, A.; Vimercati, L.; Maggiore, M.E.; D’Oria, M.T.; Hazballa, D.; et al. COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. *Microorganisms* 2021, 9, 1964, doi:10.3390/microorganisms9091964.
218. Malcangi, G.; Inchingo, A.D.; Inchingo, A.M.; Piras, F.; Settanni, V.; Garofoli, G.; Palmieri, G.; Ceci, S.; Patano, A.; Mancini, A.; et al. COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines. *Children* (Basel) 2022, 9, 249, doi:10.3390/children9020249.
219. Strappa, E.M.; Memè, L.; Cerea, M.; Roy, M.; Bambini, F. Custom-Made Additively Manufactured Subperiosteal Implant. *Minerva Dent. Oral Sci* 2022, 71, 353–360, doi:10.23736/S2724-6329.22.04640-X.
220. Barile, C.; Cianci, C.; Paramasamy Kannan, V.; Pappalettera, G.; Pappalettera, C.; Casavola, C.; Laurenziello, M.; Ciavarella, D. Damage Source Localisation in Complex Geometries Using Acoustic Emission and Acousto-Ultrasonic Techniques: An Experimental Study on Clear Aligners. *Sci Rep* 2024, 14, 21467, doi:10.1038/s41598-024-72553-2.
221. Patano, A.; Cirulli, N.; Beretta, M.; Plantamura, P.; Inchingo, A.D.; Inchingo, A.M.; Bordea, I.R.; Malcangi, G.; Marinelli, G.; Scarano, A.; et al. Education Technology in Orthodontics and Paediatric Dentistry during the COVID-19 Pandemic: A Systematic Review. *Int J Environ Res Public Health* 2021, 18, 6056, doi:10.3390/ijerph18116056.
222. Coloccia, G.; Inchingo, A.D.; Inchingo, A.M.; Malcangi, G.; Montenegro, V.; Patano, A.; Marinelli, G.; Laudadio, C.; Limongelli, L.; Di Venere, D.; et al. Effectiveness of Dental and Maxillary Transverse Changes in Tooth-Borne, Bone-Borne, and Hybrid Palatal Expansion through Cone-Beam Tomography: A Systematic Review of the Literature. *Medicina (Kaunas)* 2021, 57, 288, doi:10.3390/medicina57030288.
223. Inchingo, A.D.; Malcangi, G.; Ceci, S.; Patano, A.; Corriero, A.; Vimercati, L.; Azzollini, D.; Marinelli, G.; Coloccia, G.; Piras, F.; et al. Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. *Int J Mol Sci* 2022, 23, 8485, doi:10.3390/ijms23158485.
224. Nucera, R.; Dolci, C.; Bellocchio, A.M.; Costa, S.; Barbera, S.; Rustico, L.; Farronato, M.; Militi, A.; Portelli, M. Effects of Composite Attachments on Orthodontic Clear Aligners Therapy: A Systematic Review. *Materials* (Basel) 2022, 15, 533, doi:10.3390/ma15020533.
225. Inchingo, A.D.; Inchingo, A.M.; Malcangi, G.; Avantario, P.; Azzollini, D.; Buongiorno, S.; Viapiano, F.; Campanelli, M.; Ciocia, A.M.; De Leonardi, N.; et al. Effects of Resveratrol, Curcumin and Quercetin Supplementation on Bone Metabolism-A Systematic Review. *Nutrients* 2022, 14, 3519, doi:10.3390/nu14173519.
226. Marchetti, E.; Mummolo, S.; Di Mattia, J.; Casalena, F.; Di Martino, S.; Mattei, A.; Marzo, G. Efficacy of Essential Oil Mouthwash with and without Alcohol: A 3-Day Plaque Accumulation Model. *Trials* 2011, 12, 262, doi:10.1186/1745-6215-12-262.
227. Libonati, A.; Marzo, G.; Klinger, F.G.; Farini, D.; Gallusi, G.; Tecco, S.; Mummolo, S.; De Felici, M.; Campanella, V. Embryotoxicity Assays for Leached Components from Dental Restorative Materials. *Reprod Biol Endocrinol* 2011, 9, 136, doi:10.1186/1477-7827-9-136.
228. Bellocchio, L.; Bordea, I.R.; Ballini, A.; Lorusso, F.; Hazballa, D.; Isacco, C.G.; Malcangi, G.; Inchingo, A.D.; Dipalma, G.; Inchingo, F.; et al. Environmental Issues and Neurological Manifestations Associated with COVID-19 Pandemic: New Aspects of the Disease? *Int J Environ Res Public Health* 2020, 17, 8049, doi:10.3390/ijerph17218049.
229. Memè, L.; Sartini, D.; Pozzi, V.; Emanuelli, M.; Strappa, E.M.; Bittarello, P.; Bambini, F.; Gallusi, G. Epithelial Biological Response to Machined Titanium vs. PVD Zirconium-Coated Titanium: An In Vitro Study. *Materials* (Basel) 2022, 15, 7250, doi:10.3390/ma15207250.
230. Kiani, A.K.; Pheby, D.; Henehan, G.; Brown, R.; Sieving, P.; Sykora, P.; Marks, R.; Falsini, B.; Capodicasa, N.; Miertus, S.; et al. Ethical Considerations Regarding Animal Experimentation. *J Prev Med Hyg* 2022, 63, E255–E266, doi:10.15167/2421-4248/jpmh2022.63.S3.2768.
231. Santacroce, L.; Di Cosola, M.; Bottalico, L.; Topi, S.; Charitos, I.A.; Ballini, A.; Inchingo, F.; Cazzolla, A.P.; Dipalma, G. Focus on HPV Infection and the Molecular Mechanisms of Oral Carcinogenesis. *Viruses* 2021, 13, 559, doi:10.3390/v13040559.
232. Spirito, F.; Memè, L.; Strappa, E.M.; Gallusi, G.; Bambini, F. FT-IR Analysis of the Interface between Universal Scotchbond and Oral Mucosa: A Preliminary in-Vitro Study. *Minerva Dent. Oral Sci* 2023, 72, 45–53, doi:10.23736/S2724-6329.22.04749-0.
233. Topi, S.; Santacroce, L.; Bottalico, L.; Ballini, A.; Inchingo, A.D.; Dipalma, G.; Charitos, I.A.; Inchingo, F. Gastric Cancer in History: A Perspective Interdisciplinary Study. *Cancers (Basel)* 2020, 12, 264, doi:10.3390/cancers12020264.
234. Minervini, G.; Franco, R.; Marrapodi, M.M.; Mehta, V.; Fiorillo, L.; Badnjević, A.; Cervino, G.; Cicciù, M. Gaucher: A Systematic Review on Oral and Radiological Aspects. *Medicina (Kaunas)* 2023, 59, 670, doi:10.3390/medicina59040670.
235. Cavalca, V.; Veglia, F.; Squellerio, I.; Marenzi, G.; Minardi, F.; De Metro, M.; Cighetti, G.; Boccotti, L.; Ravagnani, P.; Tremoli, E. Glutathione, Vitamin E and Oxidative Stress in Coronary Artery Disease: Relevance of Age and Gender. *Eur J Clin Invest* 2009, 39, 267–272, doi:10.1111/j.1365-2362.2009.02094.x.
236. Fiorillo, L.; Minervini, G.; Laino, L.; Pedutto, M.; Cicciù, M.; Cervino, G. Hepatitis-Virus-Positive Patients Management in Dental Office. *Minerva Dent. Oral Sci* 2023, 72, 312–318, doi:10.23736/S2724-6329.23.04803-9.
237. Bonetti, G.; Donato, K.; Medori, M.C.; Dhuli, K.; Henehan, G.; Brown, R.; Sieving, P.; Sykora, P.; Marks, R.; Falsini, B.; et al. Human Cloning: Biology, Ethics, and Social Implications. *Clin Ter* 2023, 174, 230–235, doi:10.7417/CT.2023.2492.
238. Tinnirello, V.; Zizzo, M.G.; Conigliaro, A.; Tabone, M.;

- Ganji, N.R.; Cicio, A.; Bressa, C.; Larrosa, M.; Rappa, F.; Vergilio, G.; et al. Industrial-Produced Lemon Nanovesicles Ameliorate Experimental Colitis-Associated Damages in Rats via the Activation of Anti-Inflammatory and Antioxidant Responses and Microbiota Modification. *Biomed Pharmacother* 2024, 174, 116514, doi:10.1016/j.biopha.2024.116514.
239. Cirulli, N.; Inchingolo, A.D.; Patano, A.; Ceci, S.; Marinelli, G.; Malcangi, G.; Coloccia, G.; Montenegro, V.; Di Pede, C.; Ciocia, A.M.; et al. Innovative Application of Diathermy in Orthodontics: A Case Report. *Int J Environ Res Public Health* 2022, 19, 7448, doi:10.3390/ijerph19127448.
240. Inchingolo, F.; Hazballa, D.; Inchingolo, A.D.; Malcangi, G.; Marinelli, G.; Mancini, A.; Maggiore, M.E.; Bordea, I.R.; Scarano, A.; Farronato, M.; et al. Innovative Concepts and Recent Breakthrough for Engineered Graft and Constructs for Bone Regeneration: A Literature Systematic Review. *Materials (Basel)* 2022, 15, 1120, doi:10.3390/ma15031120.
241. Maspero, C.; Cappella, A.; Dolci, C.; Cagetti, M.G.; Inchingolo, F.; Stenza, C. Is Orthodontic Treatment with Microperforations Worth It? A Scoping Review. *Children (Basel)* 2022, 9, 208, doi:10.3390/children9020208.
242. Urzì, O.; Cafora, M.; Ganji, N.R.; Tinnirello, V.; Gasparro, R.; Raccosta, S.; Manno, M.; Corsale, A.M.; Conigliaro, A.; Pistocchi, A.; et al. Lemon-Derived Nanovesicles Achieve Antioxidant and Anti-Inflammatory Effects Activating the AhR/Nrf2 Signaling Pathway. *iScience* 2023, 26, 107041, doi:10.1016/j.isci.2023.107041.
243. Romita, P.; Ettorre, G.; Bufano, T.; Marzullo, A.; Ballini, A.; Dipalma, G.; Inchingolo, F.; Foti, C. Lichen Striatus Successfully Treated with Oral Cyclosporine. *Int J Immunopathol Pharmacol* 2017, 30, 420–422, doi:10.1177/0394632017744097.
244. Goldoni, R.; Scolaro, A.; Boccalari, E.; Dolci, C.; Scarano, A.; Inchingolo, F.; Ravazzani, P.; Muti, P.; Tartaglia, G. Malignancies and Biosensors: A Focus on Oral Cancer Detection through Salivary Biomarkers. *Biosensors (Basel)* 2021, 11, 396, doi:10.3390/bios11100396.
245. Orsini, A.; Ferretti, S.; Tamborino, F.; Cicchetti, R.; Ciavarella, D.; Seccia, B.; Basilico, R.; Colasante, A.; Marchionni, M.; Schips, L. Mastering Bladder Paraganglioma for Optimal Treatment: A Case Report of Robot-Assisted Surgery. *Ther Adv Urol* 2024, 16, 17562872241249603, doi:10.1177/17562872241249603.
246. Kiani, A.K.; Naureen, Z.; Pheby, D.; Henehan, G.; Brown, R.; Sieving, P.; Sykora, P.; Marks, R.; Falsini, B.; Capodicasa, N.; et al. Methodology for Clinical Research. *J Prev Med Hyg* 2022, 63, E267–E278, doi:10.15167/2421-4248/jpmh2022.63.S2S.2769.
247. Wisniewska, L.M.; Dohan Ehrenfest, D.M.; Galindo-Moreno, P.; Segovia, J.D.; Inchingolo, F.; Wang, H.-L.; Fernandes-Cruz, M. Molecular, Cellular and Pharmaceutical Aspects of Biomaterials in Dentistry and Oral and Maxillofacial Surgery. An Internationalization of Higher Education and Research Perspective. *Curr Pharm Biotechnol* 2017, 18, 10–18, doi:10.2174/1389201017666161213152537.
248. Sisillo, E.; Marenzi, G. N-Acetylcysteine for the Prevention of Acute Kidney Injury after Cardiac Surgery. *J Clin Pharmacol* 2011, 51, 1603–1610, doi:10.1177/0091270010384117.
249. Sisillo, E.; Ceriani, R.; Bortone, F.; Juliano, G.; Salvi, L.; Veglia, F.; Fiorentini, C.; Marenzi, G. N-Acetylcysteine for Prevention of Acute Renal Failure in Patients with Chronic Renal Insufficiency Undergoing Cardiac Surgery: A Prospective, Randomized, Clinical Trial. *Crit Care Med* 2008, 36, 81–86, doi:10.1097/01.CCM.0000295305.22281.1D.
250. Fiori, F.; Rullo, R.; Contaldo, M.; Inchingolo, F.; Romano, A. Noninvasive In-Vivo Imaging of Oral Mucosa: State-of-the-Art. *Minerva Dent Oral Sci* 2021, 70, 286–293, doi:10.23736/S2724-6329.21.04543-5.
251. Inchingolo, F.; Santacroce, L.; Ballini, A.; Topi, S.; Dipalma, G.; Haxhirexha, K.; Bottalico, L.; Charitos, I.A. Oral Cancer: A Historical Review. *Int J Environ Res Public Health* 2020, 17, 3168, doi:10.3390/ijerph17093168.
252. Contaldo, M.; Fusco, A.; Stiuso, P.; Lama, S.; Gravina, A.G.; Itro, A.; Federico, A.; Itro, A.; Dipalma, G.; Inchingolo, F.; et al. Oral Microbiota and Salivary Levels of Oral Pathogens in Gastro-Intestinal Diseases: Current Knowledge and Exploratory Study. *Microorganisms* 2021, 9, 1064, doi:10.3390/microorganisms9051064.
253. Inchingolo, A.D.; Malcangi, G.; Semjonova, A.; Inchingolo, A.M.; Patano, A.; Coloccia, G.; Ceci, S.; Marinelli, G.; Di Pede, C.; Ciocia, A.M.; et al. Oralbiotica/Oralbiotics: The Impact of Oral Microbiota on Dental Health and Demineralization: A Systematic Review of the Literature. *Children (Basel)* 2022, 9, 1014, doi:10.3390/children9071014.
254. Ricciardiello, M.; Grottola, T.; Panaccio, P.; Esposito, L.M.; Montemiro, C.; Mucilli, F.; Ciavarella, D.; di Sebastiano, P.; di Mola, F.F. Outcome after Single-Site Robotic Cholecystectomy: An Initial Single Center's Experience. *Asian J Endosc Surg* 2021, 14, 496–503, doi:10.1111/asen.12903.
255. Urzì, O.; Gasparro, R.; Ganji, N.R.; Alessandro, R.; Raimondo, S. Plant-RNA in Extracellular Vesicles: The Secret of Cross-Kingdom Communication. *Membranes (Basel)* 2022, 12, 352, doi:10.3390/membranes12040352.
256. Santacroce, L.; Inchingolo, F.; Topi, S.; Del Prete, R.; Di Cosola, M.; Charitos, I.A.; Montagnani, M. Potential Beneficial Role of Probiotics on the Outcome of COVID-19 Patients: An Evolving Perspective. *Diabetes Metab Syndr* 2021, 15, 295–301, doi:10.1016/j.dsx.2020.12.040.
257. Minervini, G.; Marrapodi, M.M.; Tirupathi, S.; Afnan, L.; Ronsivalle, V.; Cervino, G.; Cicciù, M. Prevalence of Temporomandibular Disorders (TMD) in Bleeding Disorders: A Systematic Review with Meta-Analysis. *J Oral Rehabil* 2023, 50, 1535–1543, doi:10.1111/joor.13572.
258. Ballini, A.; Santacroce, L.; Cantore, S.; Bottalico, L.; Dipalma, G.; Topi, S.; Saini, R.; De Vito, D.; Inchingolo, F. Probiotics Efficacy on Oxidative Stress Values in Inflammatory Bowel Disease: A Randomized Double-Blinded Placebo-Controlled Pilot Study. *Endocr Metab Immune Disord Drug Targets* 2019, 19, 373–381, doi:10.2174/1871530319666181221150352.
259. Ballini, A.; Santacroce, L.; Cantore, S.; Bottalico, L.; Dipalma, G.; Vito, D.D.; Saini, R.; Inchingolo, F. Probiotics Improve Urogenital Health in Women. *Open Access Maced J Med Sci* 2018, 6, 1845–1850, doi:10.3889/oamjms.2018.406.
260. Gasparro, R.; Gambino, G.; Duca, G.; Majo, D.D.; Di Liberto, V.; Tinnirello, V.; Urone, G.; Ricciardi, N.; Frinchi, M.; Rabienezhad Ganji, N.; et al. Protective Effects of Lemon Nanovesicles: Evidence of the Nrf2/HO-1 Pathway Contribution from in Vitro Hepatocytes and in Vivo High-Fat Diet-Fed Rats. *Biomed Pharmacother* 2024, 180, 117532, doi:10.1016/j.biopha.2024.117532.
261. Bernardi, S.; Memè, L.; Belfioretti, C.; Bambini, F.; Gerardi, D.; Macchiarelli, G.; Bianchi, S.; Mummolo, S. Psoriatic Arthritis Involving TMJ: A Review on Pathogenesis and Consideration on Eventual Gender Differences. *Dent J (Basel)* 2024, 12, 31, doi:10.3390/dj12020031.
262. Ballesio, I.; Marchetti, E.; Mummolo, S.; Marzo, G. Radiographic Appearance of Apical Closure in Apexification: Follow-up after 7–13 Years. *Eur J Paediatr Dent* 2006, 7, 29–34.
263. Inchingolo, A.D.; Ferrara, I.; Viapiano, F.; Netti, A.; Campanelli, M.; Buongiorno, S.; Latini, G.; Carpentiere, V.; Ciocia, A.M.; Ceci, S.; et al. Rapid Maxillary Expansion on the Adolescent Patient: Systematic Review and Case Report. *Children (Basel)* 2022, 9, 1046, doi:10.3390/children9071046.
264. Isacco, C.G.; Ballini, A.; De Vito, D.; Nguyen, K.C.D.; Cantore, S.; Bottalico, L.; Quagliuolo, L.; Boccellino, M.; Di Domenico, M.; Santacroce, L.; et al. Rebalancing the Oral Microbiota as an Efficient Tool in Endocrine, Metabolic and Immune Disorders. *Endocr Metab Immune Disord Drug Targets* 2021, 21, 777–784, doi:10.2174/1871530320666200729142504.
265. Marenzi, G.; Bartorelli, A.L. Recent Advances in the Prevention of Radiocontrast-Induced Nephropathy. *Curr Opin Crit Care* 2004, 10, 505–509, doi:10.1097/01.ccx.0000145098.13199.e8.

266. Giordano, F.; Acerra, A.; Gasparro, R.; Galdi, M.; D'Ambrosio, F.; Caggiano, M. Retrospective Radiographic Analysis of Peri-Implant Bone Loss in Mandibular Full-Arch Implant Rehabilitations. *Diagnostics* (Basel) 2024, 14, 2404, doi:10.3390/diagnostics14212404.
267. Goldoni, R.; Dolci, C.; Boccalari, E.; Inchincingo, F.; Paghi, A.; Strambini, L.; Galimberti, D.; Tartaglia, G.M. Salivary Biomarkers of Neurodegenerative and Demyelinating Diseases and Biosensors for Their Detection. *Ageing Res Rev* 2022, 76, 101587, doi:10.1016/j.arr.2022.101587.
268. Inchincingo, A.D.; Inchincingo, A.M.; Bordea, I.R.; Malcangi, G.; Xhajanka, E.; Scarano, A.; Lorusso, F.; Farronato, M.; Tartaglia, G.M.; Isacco, C.G.; et al. SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs. *Microorganisms* 2021, 9, 793, doi:10.3390/microorganisms9040793.
269. Lorusso, F.; Inchincingo, F.; Scarano, A. Scientific Production in Dentistry: The National Panorama through a Bibliometric Study of Italian Academies. *Biomed Res Int* 2020, 2020, 3468303, doi:10.1155/2020/3468303.
270. Lorusso, F.; Noubissi, S.; Francesco, I.; Rapone, B.; Khater, A.G.A.; Scarano, A. Scientific Trends in Clinical Research on Zirconia Dental Implants: A Bibliometric Review. *Materials* (Basel) 2020, 13, 5534, doi:10.3390/ma13235534.
271. Isacco, C.G.; Nguyen, K.C.D.; Pham, V.H.; Di Palma, G.; Aityan, S.K.; Tomassone, D.; Distratis, P.; Lazzaro, R.; Balzanelli, M.G.; Inchincingo, F. Searching for a Link between Bone Decay and Diabetes Type 2. *Endocr Metab Immune Disord Drug Targets* 2022, 22, 904–910, doi:10.2174/187153032266220324150327.
272. Tecco, S.; Mummolo, S.; Marchetti, E.; Tetè, S.; Campanella, V.; Gatto, R.; Gallusci, G.; Tagliabue, A.; Marzo, G. sEMG Activity of Masticatory, Neck, and Trunk Muscles during the Treatment of Scoliosis with Functional Braces. A Longitudinal Controlled Study. *J Electromogr Kinesiol* 2011, 21, 885–892, doi:10.1016/j.jelekin.2011.08.004.
273. Charitos, I.A.; Ballini, A.; Bottalico, L.; Cantore, S.; Passarelli, P.C.; Inchincingo, F.; D'Addona, A.; Santacroce, L. Special Features of SARS-CoV-2 in Daily Practice. *World J Clin Cases* 2020, 8, 3920–3933, doi:10.12998/wjcc.v8.i18.3920.
274. Shrivkumar, S.; Mehta, V.; Vaddamanu, S.K.; Shetty, U.A.; Alhamoudi, F.H.; Alwadi, M.A.M.; Aldosari, L.I.N.; Alshadidi, A.A.F.; Minervini, G. Surgical Protocols before and after COVID-19—A Narrative Review. *Vaccines* (Basel) 2023, 11, 439, doi:10.3390/vaccines11020439.
275. Lorusso, F.; Conte, R.; Inchincingo, F.; Festa, F.; Scarano, A. Survival Rate of Zygomatic Implants for Fixed Oral Maxillary Rehabilitations: A Systematic Review and Meta-Analysis Comparing Outcomes between Zygomatic and Regular Implants. *Dent J* (Basel) 2021, 9, 38, doi:10.3390/dj9040038.
276. Ciavarella, D.; Lorusso, M.; Fanelli, C.; Ferrara, D.; Esposito, R.; Laurenziello, M.; Esperouz, F.; Lo Russo, L.; Tepedino, M. The Efficacy of the RME II System Compared with a Herbst Appliance in the Treatment of Class II Skeletal Malocclusion in Growing Patients: A Retrospective Study. *Dent J* (Basel) 2024, 12, 254, doi:10.3390/dj12080254.
277. Santacroce, L.; Charitos, I.A.; Ballini, A.; Inchincingo, F.; Luperto, P.; De Nitto, E.; Topi, S. The Human Respiratory System and Its Microbiome at a Glance. *Biology* (Basel) 2020, 9, 318, doi:10.3390/biology9100318.
278. Alfieri, V.; Myasoedova, V.A.; Vinci, M.C.; Rondinelli, M.; Songia, P.; Massaiu, I.; Cosentino, N.; Moschetta, D.; Valerio, V.; Ciccarelli, M.; et al. The Role of Glycemic Variability in Cardiovascular Disorders. *Int J Mol Sci* 2021, 22, 8393, doi:10.3390/ijms22168393.
279. Galber, C.; Acosta, M.J.; Minervini, G.; Giorgio, V. The Role of Mitochondrial ATP Synthase in Cancer. *Biol Chem* 2020, 401, 1199–1214, doi:10.1515/hzs-2020-0157.
280. Campobasso, A.; Battista, G.; Fiorillo, G.; Caldara, G.; Lo Muzio, E.; Ciavarella, D.; Gastaldi, G.; Muzio, L.L. Transfer Accuracy of 3D-Printed Customized Devices in Digital Indirect Bonding: A Systematic Review and Meta-Analysis. *Int J Dent* 2023, 2023, 5103991, doi:10.1155/2023/5103991.
281. Mavriqi, L.; Lorusso, F.; Tartaglia, G.; Inchincingo, F.; Scarano, A. Transinusal Pathway Removal of an Impacted Third Molar with an Unusual Approach: A Case Report and a Systematic Review of the Literature. *Antibiotics* (Basel) 2022, 11, 658, doi:10.3390/antibiotics11050658.
282. Marenzi, G.; Kazory, A.; Agostoni, P. Ultrafiltration for Congestive Heart Failure: The Past and the Present. *Curr Opin Cardiol* 2015, 30, 186–191, doi:10.1097/HCO.0000000000000139.
283. Charitos, I.A.; Del Prete, R.; Inchincingo, F.; Mosca, A.; Carretta, D.; Ballini, A.; Santacroce, L. What We Have Learned for the Future about COVID-19 and Healthcare Management of It? *Acta Biomed* 2020, 91, e2020126, doi:10.23750/abm.v91i4.10253.
284. Papavramidou, N.; Christopoulou-Aletra, H. Medicinal Use of Leeches in the Texts of Ancient Greek, Roman and Early Byzantine Writers. *Intern Med J* 2009, 39, 624–627, doi:10.1111/j.1445-5994.2009.01965.x.
285. Dipalma, G.; Inchincingo, A.D.; Inchincingo, A.M.; Piras, F.; Carpenteriere, V.; Garofoli, G.; Azzollini, D.; Campanelli, M.; Paduanelli, G.; Palermo, A.; et al. Artificial Intelligence and Its Clinical Applications in Orthodontics: A Systematic Review. *Diagnostics* (Basel) 2023, 13, 3677, doi:10.3390/diagnostics13243677.
286. Inchincingo, R.; Maino, C.; Cannella, R.; Vernuccio, F.; Cortese, F.; Dezio, M.; Pisani, A.R.; Giandola, T.; Gatti, M.; Giannini, V.; et al. Radiomics in Colorectal Cancer Patients. *World J Gastroenterol* 2023, 29, 2888–2904, doi:10.3748/wjg.v29.i19.2888.
287. Inchincingo, A.M.; Inchincingo, A.D.; Viapiano, F.; Ciocia, A.M.; Ferrara, I.; Netti, A.; Dipalma, G.; Palermo, A.; Inchincingo, F. Treatment Approaches to Molar Incisor Hypomineralization: A Systematic Review. *J Clin Med* 2023, 12, 7194, doi:10.3390/jcm12227194.
288. Malcangi, G.; Patano, A.; Pezzolla, C.; Riccaldo, L.; Mancini, A.; Di Pede, C.; Inchincingo, A.D.; Inchincingo, F.; Bordea, I.R.; Dipalma, G.; et al. Bruxism and Botulinum Injection: Challenges and Insights. *J Clin Med* 2023, 12, 4586, doi:10.3390/jcm12144586.
289. Inchincingo, A.M.; Malcangi, G.; Ferrante, L.; Del Vecchio, G.; Viapiano, F.; Mancini, A.; Inchincingo, F.; Inchincingo, A.D.; Di Venere, D.; Dipalma, G.; et al. Damage from Carbonated Soft Drinks on Enamel: A Systematic Review. *Nutrients* 2023, 15, 1785, doi:10.3390/nu15071785.
290. Alam, K.; Al-Ghaithi, A.; Piya, S.; Saleem, A. In-Vitro Experimental Study of Histopathology of Bone in Vibrational Drilling. *Med Eng Phys* 2019, 67, 78–87, doi:10.1016/j.medengphy.2019.03.013.
291. F. Gianfreda, L. Nucci, P. Boller, A. Danieli, A. Palermo, P. Salvadori, M. Gargari, M. Martelli. A rare case of impacted mandibular premolar associated to dentigerous cyst and periodontal lesion: clinical management and histological analysis. *Oral and Implantology*, Vol. 16. No. 3 (2024), 113-118.
292. A. Barlattani JR, R. Franco, M. Martelli, F. Gianfreda, R. Ferro, M. Basili, P. Boller, Guided Bone Regeneration in Patients Taking Biphosphonates: Two Cases Series, *Oral and Implantology*, (Rome) 2019;12:194-204.
293. Fracture resistance of monolithic zirconia cantilevered frameworks in complete arch-prostheses supported by tilted or parallel implants ORAL and Implantology2019 I Journal article EID: 2-s2.0-8507323459 Part of ISBN: 20352468 19745648 CONTRIBUTORS: de Francesco, M.; Di Fiore, A.; Bruno, G.; Gargari, M.; Martelli, M.; Barnaba, P.; Marino, M.; Quercia, A.; Ceruso, F.M.